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Viral proteins have a multitude of roles during pathogenesis and replication, in order 
to maximise likelihood of virus survival during infection. However, in many cases 
viral proteins are cytotoxic, resulting in the decimation of immune cells, imbalanced 
antiviral responses and, in the case of deadly haemorrhagic viruses, organ failure, 
often leading to death of the host. This is largely the effect of ebolaviruses during 
infections in humans, as the increased understanding of this virus has allowed us to 
recognize how its proteins are involved in pathogenesis. However, there is still a 
substantial amount of knowledge to be discovered about this deadly virus. Here, we 
attempt to increase our knowledge on cytotoxicity of several Ebola virus proteins, 
namely VP24 and delta-peptide. Our journey in the past three years has uncovered 
a novel effect of VP24 in mammalian cells. Largely known for its interferon 
antagonism, prolonged incubation of VP24 appears to upregulate markers of cell 
cycle arrest, such as p21. Furthermore, we report increased expression of γH2AX, 
a marker for DNA damage. In the case of delta-peptide, we attempted several 
techniques for gathering structure-function data, such as nuclear magnetic 
resonance imaging to lipidic cubic phase crystallography. We have managed to 
generate peptide crystals in a lipid environment, with the intention of carrying out x-
ray scatter to generate a structure. By increasing our knowledge on viral proteins, 
every small piece of research forms a chain of information with the hopes to 
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1.1 Overview of Ebolavirus 
1.1.1 History of Ebolavirus 
On the 26th of August 1976, a 44 year-old teacher visited the mission hospital of his 
local village called Yambuku, Zaire (now known as Democratic Republic of Congo). 
With the intent of seeking medical attention for an illness he acquired resembling 
malaria, he was given an injection of chloroquine. However, syringe needles were 
often reused on several patients at the hospital, and without knowing that the index 
case was infected with a very deadly unknown pathogen, the disease swiftly spread 
to other patients. The destruction that ensued was rapid; within a little more than a 
month, 280 out of the 318 people that were infected succumbed to the virus 
(Commission, 1978). Blood samples from one of the Belgian nurses present at the 
Mission Hospital were sent in a Thermos flask to Antwerp for further analysis, as no 
one knew what virus was responsible for this outbreak. At the time, researchers were 
aware of a deadly filovirus circulating in Africa called Marburg virus, which also 
causes haemorrhagic fever. All the more coincidentally, another deadly 
haemorrhagic virus was causing an outbreak in Sudan with similar mortality as seen 
in Yambuku (Team, 1978). The research team in Antwerp collaborated with several 
other established research centres including Porton Down in the UK and the CDC 
Atlanta, Georgia, where cultures of the virus were observed under electron 
microscopy. It was at this point where the newly discovered virus was given its name: 
Ebola virus, after the Ebola river near Yambuku (Pattyn et al., 1977). Interestingly, 
the pathogen responsible for the 1976 outbreak in Sudan was revealed to be Sudan 




1.1.2 Phylogeny and Genome 
Ebolaviruses are single-sense negative-strand RNA viruses. They belong to the 
family of filoviridae, which is comprised of three genera: Ebolavirus, Cuevavirus and 
Marburgvirus. There are currently five members pertaining to the Ebolavirus genus; 
Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) Bundibugyo virus 
(BDBV) and Reston virus (RESTV) (Maes et al., 2019). A new filovirus has been 
recently discovered in Africa named Bombali virus (BOMV), retaining 55-59% 
similarity at nucleotide level and 64-72% similarity at amino acid level [Figure 1] 
(Goldstein et al., 2018). There is no evidence of BOMV infecting humans to date. 
Due to its discovery in August 2018, it has yet to be assigned taxonomically by the 
International Committee on Taxonomy of Viruses.  
 
Figure 1. Phylogenetic Analysis of filoviruses based on full genome 
sequences.  
This phylogenetic tree represents how closely related the different members of the 
filoviridae are. BOMV has also been included. Adapted from The discovery of 





The genome length across Ebolaviruses is approximately 19 kilobases in length, 
comprising of 7 genes; nucleoprotein (NP), viral protein (VP)35, VP40, glycoprotein 
(GP), VP30, VP24 and the L polymerase protein (L), separated by intergenic regions 
and overlaps [Figure 2] (Emanuel, Marzi and Feldmann, 2018). However, the 
genome organisation differs between EBOV and RESTV. EBOV contains several 
Figure 2. Filovirus genome organisation.  
The schematics depict how the genes are arranged, highlighting the intergenic 
regions and gene overlaps between the species. The schematic representing 
EBOV may also represent BDBV, TAFV and SUDV as they are arranged in similar 
fashion. Figure adapted from Filoviruses: Ecology, Molecular Biology, and 




gene overlaps between VP35 and VP40, GP and VP30, and VP24 and L (Ikegami 
et al., 2001). RESTV however does not retain an overlap between GP and VP30.  
Each gene of Ebolaviruses contains a single open reading frame (ORF), with the 
exception of GP, containing 3 overlapping ORFs, each leading to production of 
different variants of GP products [Figure 3] (Volchkov et al., 1995; Sanchez et al., 
1996). This is due to site-specific transcriptional editing by L polymerase, resulting 
in secreted (s)GP being produced from undedited RNA, whereas the full length GP 
is produced when an additional adenosine is inserted into the transcript. Lastly, when 
two aditional adenosine residues are added, a third GP gene product is produced 
called small soluble (ss)GP (Mehedi et al., 2011). 
 
1.1.3 Ecology and Epidemiology 
Almost all Ebolaviruses, with the exception of Reston virus, are found in Africa. The 
reservoir for this deadly virus has yet to be conclusively determined, though it is 
highly suspected that fruit bats are the reservoir, as experimental inoculation of the 
virus did not result in illness despite viral replication (Swanepoel et al., 1996). A 
survey conducted in Gabon during Ebola virus outbreaks between 2001 and 2003 
also found viral RNA in liver and spleen samples of 3 different species of fruit bats 
(Leroy et al., 2005). The hypothesis of fruit bats being the reservoir also stems from 
Figure 3. Open Reading Frames in the GP gene. 
The first 295 amino acids of all GP gene products are the same but differ towards the 
C-terminal end. The most expressed product from the GP gene is sGP, followed by GP 




the fact that every outbreak appears to have resulted from environments shared by 
humans or susceptible hosts, and fruit bats (Groseth, Feldmann and Strong, 2007). 
Interestingly, fruit bats outside of Africa have been reported to host filoviruses such 
as Lloviu Cuevavirus in Spain, Hungary and China, strongly suggesting that bats are 
reservoirs of filoviruses and that these viruses are globally distributed, despite not 
being pathogenic in humans compared to the filoviruses found in Africa (Hayman, 
2016). Another question that is often pondered is whether seasonal changes affect 
transmission as this may affect the distribution of bats, for example; food scarcity, 
weather patterns or pregnancy, as these factors may affect bat migrations resulting 
in closer contact between humans or other hosts, making the spillovers of virus 
between bats and humans much more likely (Leroy et al., 2005). Risk factors have 
been identified for potential outbreaks, as many index patients have lifestyles that 
brings them into close proximity with bats such as hunters or workers entering 
forests, caves or abandoned mines (Groseth, Feldmann and Strong, 2007). Human 
to human transmission of the virus is very efficient for a virus only transmitted through 
infected fluids. This was seen during the 2014-2016 Ebola virus outbreak as the 
index patient was an 18 month old boy from a village in Guinea’s Guéckédou 
prefecture called Meliandou in December 2013 (Baize et al., 2014; Timothy et al., 
2019). By February-March 2014 patients were tested positive for Ebola virus 
infection in Macenta and Kissidougu.  By the end of March the virus has reached the 
capital city of Conakry, due to an infected individual related to the index case’s 
extended family, which initiated multiple chains of transmission (Kaner and Schaack, 
2016). This is testament to how rapid Ebola virus can be transmitted by human to 







Table 1. Chronology of previous Ebola Virus disease outbreaks 
This table was adapted from the World Health Organisation fact sheet on Ebola Virus 
Disease page. Accessed on 15th of April, 2019. * Includes suspect, probable and 




species Cases Deaths Case fatality 
2018-2019 DRC EBOV Ongoing   
2018 DRC EBOV 54 33 61% 
2017 DRC EBOV 8 4 50% 
2015 Italy EBOV 1 0 0% 
2014 DRC EBOV 66 49 74% 
2014 Spain EBOV 1 0 0% 
2014 UK EBOV 1 0 0% 
2014 USA EBOV 4 1 25% 
2014 Senegal EBOV 1 0 0% 
2014 Mali EBOV 8 6 75% 
2014 Nigeria EBOV 20 8 40% 
2014-2016 Sierra Leone EBOV 14124* 3956* 28% 
2014-2016 Liberia EBOV 10675* 4809* 45% 
2014-2016 Guinea EBOV 3811* 2543* 67% 
2012 DRC BDBV 57 29 51% 
2012 Uganda SUDV 7 4 57% 
2012 Uganda SUDV 24 17 71% 
2011 Uganda SUDV 1 1 100% 
2008 DRC EBOV 32 14 44% 
2007 Uganda BDBV 149 37 25% 
2007 DRC EBOV 264 187 71% 
2005 Congo EBOV 12 10 83% 
2004 Sudan SUDV 17 7 41% 
2003 Congo EBOV 35 29 83% 
2003 Congo EBOV 143 128 90% 
2001-2002 Congo EBOV 59 44 75% 
2001-2002 Gabon EBOV 65 53 82% 





1 1 100% 
1996 Gabon EBOV 60 45 75% 
1996 Gabon EBOV 31 21 68% 
1995 DRC EBOV 315 254 81% 
1994 Côte d'Ivoire TAFV 1 0 0% 
1994 Gabon EBOV 52 31 60% 
1979 Sudan SUDV 34 22 65% 
1977 DRC EBOV 1 1 100% 
1976 Sudan SUDV 284 151 53% 





1.1.4 Ebola Virus Disease 
Ebola virus enters the human body through mucosal surfaces and sites of skin injury. 
At early stages of infection, an asymptomatic incubation period exists whereby an 
individual would continue with their daily routine. However, as viral load increases 
during incubation, initial non-specific symptoms of Ebola virus disease (EVD) 
become apparent such as fatigue, muscle weakness and malaise, followed by onset 
of fever (Bwaka et al., 1999). At around 1 week of illness, further symptoms include 
vomiting, watery diarrhoea and nausea, at which this point the infected individual is 
considered to be most infectious (Baseler et al., 2017). A diffuse maculopapular rash 
becomes visible. Week 2 is when EVD peaks as organ damage occurs such as renal 
failure and hepatic injury [Figure 4]. It is at this point where haemorrhaging occurs. 
Figure 4. Timeline of the typical case of Ebola Virus Disease in humans.  
The timeline of EVD shows that peak illness is associated with peak viremia, as 





Furthermore, EVD causes central nervous system dysfunction resulting in 
neuromuscular impairment and  meningoencephalitis befalls the infected individual 
at this stage of infection (Chertow et al., 2016). Other organs affected include eyes, 
as ocular disturbances resulting in blurred vision and onset of uveitis occur in late 
stages of infection, and the heart, as myocardial disfunction has been detected in 
infected individual. During week 2 and week 3 of infection viral load begins to 
decrease. Week 4 is considered to be the recovery phase for survivors of EVD as 
tissue damage repair occurs. However, sites of immunological privilege allow for 
persistence of the virus such as eyes, central nervous system and testis (Baseler et 
al., 2017). Symptoms often reported by survivors include uveitis, blurred vision, 
muscular pain and fatigue. 
 
 Current literature has suggested that factors present in acute phase of EVD may 
determine chances of survival. Factors present in the early stages of infection 
include viral load and activation of various host pathways in response to the infection. 
With regards to viral load, ct (cycle threshold) values by quantitative real-time PCR 
have been fairly useful to determine outcome. CT values are defined as the number 
of cycles during PCR that are required for florescent signal to exceed background 
fluorescence, thus giving you a positive result. Therefore, a low ct value indicates 
high amounts of viral load.  During infection, low ct values ~12 suggest fatal outcome 
whereas ~30 suggest survival (Fitzpatrick et al., 2015). However, the issue lies when 
ct values fall in the middle of these two extremes, by which point it may be considered 
that an individual would have an equal chance of fatal or survival chance. By looking 
at gene pathways one could further predict the severity of EVD and tailor the 
treatment required for the patient. Some of the biggest differences between fatal and 
survivor outcome was the activation of interferon signalling pathways, as a high 
amount of activation was correlated with fatal outcome (X. Liu et al., 2017). 
Furthermore, differences in types of immune cell abundance was also associated 
with patient outcome, as fatal cases often had less circulating CD14+ monocytes 
and lower NK cells in peripheral blood (X. Liu et al., 2017). These indicators suggest 




Therefore, understanding determinants for outcome of EVD may be of great use for 
diagnostic and treatment approaches. 
 
1.2 Ebolavirus Proteins 
*The following sections on Ebolavirus proteins and their roles were taken from our 
published review: Ebolaviruses: New roles for old proteins (Cantoni and Rossman, 




VP24 is one of the most studied filovirus proteins, with the majority of studies 
focusing on its primary role in inhibiting the host IFN response. VP24 is known to 
inhibit IFN-α/β and IFN-γ activation by binding to key host proteins from the 
karyopherin α family: karyopherin α1, α5 and α6, preventing their binding to and the 
subsequent nuclear import of signal transducer and activator of transcription 1 
(STAT1) (Reid et al., 2006). In addition, VP24 blocks IFN signalling by directly 
binding to STAT1, preventing its phosphorylation, nuclear import and transcription 
of interferon stimulated genes (ISG) (Reid et al., 2006; Zhang, Bornholdt, et al., 
2012; Xu et al., 2014). Recent data suggests VP24 is also able to block IFN induction 
by supressing nuclear factor-kappa B (NF-kB) activation following tumour necrosis 
factor alpha (TNF- α) stimulation  (Guito et al., 2017) and by supressing retinoic acid-
inducible gene I (RIG-I) dependent activation of IFN-γ1 gene expression (F. He et 
al., 2017). Furthermore, the innate response antagonist domains (IRAD) in EBOV 
VP24 and VP35 have been implicated in preventing the maturation of EBOV-infected 
dendritic cells by modulating global gene expression (Lubaki et al., 2013; Ilinykh et 
al., 2015). This effect required both VP24 and VP35 IRAD domains, though the VP24 
IRAD domain alone was sufficient to down-regulate cytokine signalling pathways 
(Ilinykh et al., 2015). These results highlight the importance of cooperative action of 




VP24 has also recently been seen to function in capsid assembly (Huang et al., 
2002). NP and VP35 are known to be the major components of the viral 
nucleocapsid, though VP24 is weakly associated and may act as a catalyst for 
particle formation (Huang et al., 2002). Further evidence for a structural role of VP24 
comes from the observation that N- or C-terminal deletions in VP24 inhibited the 
formation of nucleocapsid-like structures mediated by VP24, VP35 and NP co-
expression (Han et al., 2003). It was suggested that the N-terminal domain of VP24 
facilitates capsid formation by mediating protein-protein interactions. This is 
supported by the observation that mutation of the VP24 N-terminal domain results in 
protein aggregation (Han et al., 2003). A recent study confirmed the interaction 
between VP24 and NP, showing that VP24 residues V170 and N171 are located on 
a highly-conserved exposed loop that interacts with NP during nucleocapsid 
assembly (Banadyga et al., 2017). Co-expression of VP24 and VP40 results in a 
greater production of virus-like particles (VLPs) than when VP40 is expressed alone 
(Licata et al., 2004). Similarly, in live EBOV infection, VP24 small interfering RNA 
(siRNA) knockdown decreases viral budding and increases the retention of viral 
proteins within the cell (Mateo et al., 2011). Further evidence suggests that VP24 
binds to VP35 on the outer surface of the nucleocapsid where it organizes the 
adjacent NP layer, promoting nucleocapsid stability and explaining the observed 
interactions between NP, VP24 and VP35 during nucleocapsid formation (Beniac et 
al., 2012).  
In addition to its role in nucleocapsid stability, VP24 may be necessary for 
incorporation of the viral RNA genome into the nucleocapsid. Several studies have 
shown that VP24, together with VP35, induce conformational changes in NP that are 
necessary for vRNA encapsidation (Huang et al., 2002; Noda et al., 2005; 
Watanabe, Noda and Kawaoka, 2006). It was shown that VP24 may be directly 
involved in length-dependent RNA interactions and packaging (Watt et al., 2014). In 
the study, transcription and replication-competent virus-like particles (trVLPs) were 
analysed for RNA content and a significant reduction of packaged RNA was 
observed when VP24 was knocked-down with an interfering micro-RNAs (miRNA). 
The trVLPs that were produced showed a twofold reduction in RNA content and a 




RNA packaging. Furthermore, disruption of the VP24-NP interaction reduced RNA 
packaging and resulted in a significant reduction in reporter activity, highlighting the 
importance of VP24 in RNA packaging (Banadyga et al., 2017). In addition, trVLP 
reporter gene activity was significantly affected by the presence of VP24 in a 
genome-length dependent manner. Using the trVLP tetra-cistronic genome system, 
the presence of VP24 during VLP production resulted in a 25-fold increase in 
reporter gene activity upon subsequent infection, whereas the presence of VP24 had 
no effect when mono-cistronic mini-genome systems were used in the trVLP, 
suggesting a genome length-dependent role for VP24 in RNA packaging and 
VLP/virion infectivity. Surprisingly, VP24 may also have a length-dependent role in 
transcriptional regulation. It was observed that VP24 moderately inhibited the 
expression of reported genes from mono-cistronic mini-genome plasmids 
(Watanabe et al., 2007). However, VP24 expression had no effect on protein 
expression from the trVLP tetra-cistronic genomes (Watt et al., 2014). Whilst the 
impact of VP24 on protein expression is not clear, VP24 itself may be subject to 
length-dependent transcriptional regulation. Recent work has implicated the length 
of the intergenic region (IR) between VP30-VP24 as having a significant impact on 
VP24 expression by regulating transcription initiation frequency (Neumann, 
Watanabe and Kawaoka, 2009; Brauburger et al., 2014). The importance of the 
broad range of VP24 functions during virus replication are highlighted by the fact that 
it has not been possible to create a VP24-deficient recombinant EBOV, even when 
VP24 is supplied in trans (Mateo et al., 2011). 
1.2.2 VP35* 
As with VP24, VP35 is primarily known for its multifaceted ability to suppress the 
host cell immune response. VP35 is a type-I interferon antagonist, inhibiting the 
activation of interferon regulatory factor (IRF)-3 via double-stranded RNA binding 
and reducing IFN-α/β production by inhibiting RIG-I signalling (Basler et al., 2000; 
Cárdenas et al., 2006; Luthra et al., 2013). VP35 also blocks IFN production by 
increasing protein inhibitor of activated STAT 1 (PIAS1)-mediated SUMOylation of 
IRF-7, thus inhibiting IFN production following toll-like receptor (TLR) and RIG-I 




functionally equivalent to the human immunodeficiency virus (HIV-1) trans-activator 
of transcription (Tat) protein and important for viral evasion of the innate immune 
response (Haasnoot et al., 2007). Together, there is significant evidence 
demonstrating VP35’s intricate ability to inhibit innate immune signalling and the host 
antiviral response [Figure 5].  
Recent work suggests that VP35 may have more diverse functions during virus 
replication, as VP35 was shown to interact with L and facilitate genome transcription 
through the formation of the RdRp complex and genome packaging through 
association with NP (Groseth et al., 2009; Prins et al., 2010; Kirchdoerfer et al., 
2016). The first 450 residues of VP35 appear to be essential for binding to L and 
thus RdRp function, whereas the C-terminus associates with NP, thus linking NP-L 
during nucleocapsid assembly (Prins et al., 2010; Trunschke et al., 2013). N-terminal 
deletions in VP35 block these interactions and were sufficient to inhibit the replication 
and transcription of a EBOV mini-genome system (Trunschke et al., 2013). The role 
of the VP35 C-terminus in capsid assembly is perhaps surprising, as this region 




evasion. However, this domain contains several conserved stretches of basic 
residues, the central region is involved in dsRNA binding and IFN inhibition whereas 
a preceding stretch mediates interaction with NP (Prins et al., 2010). Further 
research found the VP35-NP interaction controls the switch between RNA-bound NP 
and free NP, thus switching between genome replication and genome packaging in 
the nucleocapsid (Leung et al., 2015). A N-terminal peptide derived from the VP35 
NP-binding protein region (NPBP) binds NP with high affinity causing the release of 
Figure 5. Multiple roles of VP35 during virus replication 
VP35 inhibits the type-I IFN response through several different mechanisms. VP35 
can bind to dsRNA, preventing the activation of RIG-I signalling. In addition, VP35 
blockade of IRF3 and IRF7 phosphorylation inhibits the production of IFN-β. 
Recent studies have also highlighted the importance of VP35 in regulating NP–
RNA association. During viral genome replication, the VP35 N-terminal peptide 
binds to NP, enabling the vRNA to associate with the RdRp complex for replication. 
During virus assembly, VP35 disassociates, enabling NP to oligomerise, bind RNA, 
and form the nucleocapsid. 5’PPP, 5’ triphosphate; dsRNA, double-stranded RNA; 
IFN, interferon; IKK, inhibitor of nuclear factor kappa B kinase subunit epsilon; IRF, 
interferon regulatory factor; MAVS, mitochondrial antiviral-signalling protein; MDA5, 
melanoma differentiation-associated protein 5; NP, nucleoprotein; PACT, protein 
activator of the interferon-induced protein kinase; RdRp, RNA-dependent RNA 
polymerase; RIG-I, retinoic acid-inducible gene I; TANK, tumour necrosis factor–
receptor-associated factor family member–associated nuclear factor kappa B 
activator; TBK1, tumour necrosis factor–receptor-associated factor family member–
associated nuclear factor kappa B activator binding kinase 1; TRAF3, tumour 




RNA from NP and resulting in the activation of genome transcription and the 
inhibition of NP oligomerization [Figure 5] (Leung et al., 2015). Additional 
investigation of VP35-NP binding showed two further interaction sites. Hydrophobic 
VP35-NP binding at these sites inhibited NP oligomerisation and prevented NP-RNA 
binding by blocking access to the RNA binding domain (Kirchdoerfer et al., 2015). 
Work by Leung et al. suggest that during nucleocapsid formation the NPBP peptide 
first disassociates from NP, then RNA binds to NP followed by NP oligomerization. 
In contrast, Kirchdoerfer et al. show that monomeric NP has no significant affinity for 
RNA, suggesting that the NPBP peptide would be displaced by an additional NP 
molecule, causing NP oligomerization which would then allow for RNA binding. 
However, in either process, VP35-NP interactions are crucial for virus replication and 
are being explored as targets for future therapeutics (Ren et al., 2016; G. Liu et al., 
2017).  
VP35 also undergoes further protein-protein interactions that may affect viral 
genome transcription through the interaction with the cytoplasmic dynein light chain 
(LC8) (Kubota et al., 2009). LC8 is a highly conserved 8kDa subunit of the 
cytoplasmic dynein motor complex but can also exist as a dimer in soluble form, 
where it can affect viral transcription and assembly (Tan et al., 2007; Kirkham et al., 
2016). LC8 was seen to stabilize VP35 N-terminal oligomerisation in a dose-
dependent manner and enhance viral genome synthesis (Luthra et al., 2015). It was 
noted that LC8 functions mostly in the early stages of infection, enhancing early viral 
gene expression before the host cells are able to establish the antiviral state. Thus, 
VP35 modulation of viral RNA transcription can facilitate virus replication while 
simultaneously enhancing immune evasion.  
 
1.2.3 VP30* 
The minor nucleoprotein VP30 has the primary role of initiating EBOV transcription 
(Weik et al., 2002). It is dynamically phosphorylated, whereby upon phosphorylation, 
transcription is negatively regulated, enabling binding to NP (Modrof et al., 2002; 
Biedenkopf, Lier and Becker, 2016). In turn this permits interactions that regulate 




presence of an unconventional zinc-binding motif, facilitating RNA binding and 
increasing viral genome transcription (Modrof, Becker and Mühlberger, 2003; John 
et al., 2007; Biedenkopf et al., 2016; Schlereth et al., 2016).  
In addition to its RNA binding role in transcription, VP30 also interferes with cellular 
RNA silencing (Fabozzi et al., 2011). In the presence of siRNA, VP30 was seen to 
interact with the essential RNA interference (RNAi) protein Dicer, though the VP35 
N-terminus RNA binding domain was not required for the interaction or for the 
suppression of RNAi [Figure 6]. As with the RNA silencing suppressor activity of 
VP35, the exact role of RNAi in antiviral immunity is not clear, nor is the consequence 
on EBOV replication of blocking miRNA/siRNA processing as mediated by VP30 (Li 
et al., 2013). However, despite the fact that RNA binding is not required for RNA 
silencing suppression, VP30 was seen to bind to a variety of non-viral RNAs. VP30-
RNA binding required specific base composition and structure of the target RNA 
molecule (Schlereth et al., 2016), though it is not clear if there is a function of VP30 
binding to non-viral RNA or if this is a consequence of its necessary binding to viral 
RNA during transcription.  
 
Figure 6. Ebolavirus proteins VP30, VP35, and VP40 are suppressors of RNA 
silencing  
Cellular RNA interference requires the assembly of the Dicer:TRBP:PACT 
complex. VP30 inhibits RNAi by interacting with Dicer, preventing TRBP binding 
and complex activity. VP35 also inhibits complex assembly by binding TRBP and 
PACT, preventing their association with Dicer. VP40 suppresses RNAi during 
infection or when transferred to bystander immune cells through exosomes, though 
the mechanism by which VP40 inhibits the Dicer machinery is currently unknown. 
PACT, protein activator of the interferon-induced protein kinase; RNAi, RNA 






The matrix protein VP40 has roles predominantly in virus assembly and budding 
(Ruigrok et al., 2000; Pleet et al., 2017). VP40 can assemble either as a hexamer, 
which appears to be involved in budding, or as an octamer that functions in genome 
replication and RNA binding (Timmins, Schoehn, Kohlhaas, et al., 2003; Bornholdt 
et al., 2013). Most research has focused on the role of VP40 in assembly and 
budding, however, recent studies have begun to elucidate novel roles. 
VP40 is known to be sufficient to mediate the formation and budding of VLPs; 
however, recent results have demonstrated that VP40 induces the formation for 
exosomes that are capable of inducing bystander cell death (Harty et al., 2000; Pleet 
et al., 2016). Exosome release has been seen in virally-infected cells and VP40 
expression was seen to increase the expression of several endosomal sorting 
complex required for trafficking (ESCRT) proteins involved in exosome biogenesis, 
including: tumor susceptibility gene 101 (TSG101), vacuolar protein-sorting-
associated protein 25 (VPS25), and VPS36 (Wauquier et al., 2010; Pleet et al., 
2016). This is consistent with previous reports showing VP40 utilizing ESCRT 
proteins to aid viral budding, though how VP40 switches between budding and 
exosome release is not clear (Licata et al., 2003; Timmins, Schoehn, Ricard-Blum, 
et al., 2003; Han et al., 2015).  
Transfer of VP40-induced exosomes to naïve T-lymphocytes and monocytes 
induced apoptosis and significantly reduced cell viability similarly to that seen when 
exosomes from virally infected cells were used (Wauquier et al., 2010; Pleet et al., 
2016). However, Pleet et al. noted that the presence of VP40 in the exosomes 
caused a downregulation of miRNA machinery in both the donor and recipient cells, 
including a reduction in the expression of Dicer, argonaute-1, and Drosha [Figure 6]. 
It was previously noted that VP35, VP30 and VP40 are capable of interacting with 
the miRNA/RNAi pathway (Fabozzi et al., 2011), however, this was the first 
demonstration that the suppression of RNA silencing can be transferred to naïve 
cells in the absence of virus. Currently, the precise mechanism in which VP40 
interacts with miRNA machinery has yet to be characterised and it is not yet known 
if the action of VP40 on the miRNA machinery directly causes apoptosis or if the 




induction of apoptosis. However, the repression of key proteins in the miRNA 
pathway has been previously linked to the induction of apoptosis, thus the 
suppression of RNA silencing may serve both to directly counteract the innate 
cellular immune response and to induce apoptosis of bystander immune cells, 
blocking the activation of adaptive immunity (Han et al., 2013; Pleet et al., 2016, 
2017). 
Due to the essential role of VP40 in viral assembly and budding, several studies 
have looked at inhibiting VP40 for the creation of new antiviral therapeutics (R. V 
Stahelin, 2014; Biedenkopf et al., 2017). As VP40 also plays a role in immune 
evasion (via RNAi suppression and exosome-bystander cell death), there is 
increased motivation for developing therapeutics that target one or multiple of the 
functions of VP40. It is known that viral replication requires VP40 phosphorylation at 
tyrosine 13 by the cellular tyrosine kinase Abelson murine leukemia viral oncogene 
homolog 1 (c-Abl1) (García et al., 2012). In addition, recent results showed that 
cyclin-dependent kinase 2 (Cdk2) in complex with Cyclin A or Cyclin E 
phosphorylated exosomal VP40 at serine-233 (Pleet et al., 2016). Thus, the 
inhibition or modulation of VP40 phosphorylation may be a target for new 
therapeutics. Lastly, Pleet et al. showed that treatment with the FDA-approved drug 
Oxytetracycline reduced VP40-exosome release and significantly increased donor 
cell viability upon treatment with VP40-exosomes, further suggesting that targeting 
the secondary functions of VP40 may be a new approach for developing antivirals 
for EVD.  
 
1.2.5 Glycoprotein* 
The GP gene has been shown to encode for three different products due to 
transcriptional editing by L polymerase: full length GP which consist of GP1 (receptor 
binding) and GP2 (viral fusion) subunits, soluble GP (sGP) which lacks the 
transmembrane domain, and small soluble GP (ssGP) (Volchkova et al., 1998; 
Mehedi et al., 2011). Due to furin cleavage of sGP, a smaller cleaved fragment is 
also produced, called Δ-peptide (V.A., H.-D. and V.E., 1999). GP is the only viral 




fusion (Shimojima et al., 2006; Lee and Saphire, 2009; Moller-Tank et al., 2015). 
Ebolaviruses are thought to predominantly enter cells via GP-dependent 
macropinocytosis though other mechanisms have been reported, depending on 
factors such as host cell type (Nanbo et al., 2010; Aleksandrowicz et al., 2011). After 
entry, GP directs fusion between the viral membrane and endo-lysosomes that 
contain the viral receptor Niemann-Pick C1 (NPC1) and two pore segment channel 
2 (TPC2), enabling release of the viral genome (Mingo et al., 2015; Simmons et al., 
2016). During the 2014-2016 outbreak, a mutation in GP at A82V was detected with 
high frequency (Diehl et al., 2016; Urbanowicz et al., 2016; Dietzel et al., 2017). It is 
worth mentioning that Urbanowicz et al reported an increase in infectivity using 
pseudotyped virus as opposed to live virus, however, this mutation increased GP 
membrane fusion activity and increased infectivity in a variety of cell types, including: 
Chimpanzee fibroblasts (S008842), Rhesus epithelial (FRhK4), African green 
monkey epithelial (Vero) and human dendritic cells. The authors propose that this 
mutation is likely a result of EBOV adaptation to the human host, as several viral 
variants have been seen to increase human cell infectivity while decreasing virus 
entry in nonhuman primates (Hoffmann et al., 2017; Ruedas et al., 2017; Wang et 
al., 2017). Thus, the specific nature of protein function needs to be considered in the 
context of the given host.  
GP has been shown to have a multitude of secondary roles beyond attachment and 
fusion that affect both virus replication and pathogenicity. Several studies have 
shown that GP contributes to EBOV virulence; however, it is not sufficient on its own 
to be defined as a virulence marker, despite having marked effects beyond entry and 
fusion (Groseth et al., 2012). EBOV GP expression has been well established as 
having a cytotoxic effect on host cells (Yang et al., 2000; Ray et al., 2004; Sullivan 
et al., 2005). GP cytotoxicity is mediated through the mucin-like domain and its effect 
on the extracellular signal–regulated kinase (ERK) mitogen-activated protein kinase 
(MAPK) pathway (Zampieri et al., 2007). EBOV GP reduces the phosphorylation and 
catalytic activity of ERK2 resulting in the loss of cell adherence, cell rounding and 
the induction of non-apoptotic cell death. The decrease in ERK2 activity was also 
necessary for GP-induced downregulation of αV integrin expression; further 




product, Δ-peptide, may play a role in EBOV pathogenicity by acting as a viroporin 
(Gallaher and Garry, 2015). Δ-peptide is able to form pores in the plasma membrane 
of mammalian cells, increasing ion permeability and causing cytotoxicity (J. He et 
al., 2017). However, it is not known if the Δ-peptide can be released from cells or if 
its induction of cytoxicity is limited to within the infected cell. In order to regulate the 
toxicity caused by GP and its cleavage products at early stages of infection, GP 
expression is dynamically regulated (Alazard-Dany et al., 2006). The balance and 
timing of EBOV GP/sGP/ssGP/shed-GP/ Δ-peptide expression has been found to 
be pivotal in virus replication, affecting not only cell death but viral assembly and 
budding (Mohan et al., 2015).  
Whilst VP40 expression is sufficient to produce VLPs, GP expression enhances VLP 
generation, suggesting a possible secondary role for GP in viral egress (Licata et al., 
2004). Recent work suggests that GP does not directly affect viral assembly or 
budding, but rather counteracts the cellular budding restriction factor tetherin 
(Kaletsky et al., 2009). In the absence of GP, VLPs assemble and bud but are 
retained on the cell surface through the anti-viral tethering actions of the tetherin 
protein. GP expression enabled VLP release but did not affect tetherin cell-surface 
localization nor was a specific GP-tetherin interaction found (Lopez et al., 2010). It 
was shown that the GP glycosylation and its receptor-binding domain (RBD) were 
critical for anti-tetherin activity, though mutation of the RBD did not affect interactions 
with tetherin and inhibition of GP-NPC1 binding did not affect the anti-tetherin activity 
(Brinkmann et al., 2016). Instead, it is thought that GP is specifically able to block 
the association between VP40 and tetherin, though the nature of tetherin-VP40 
interaction and the mechanism of GP inhibition is not known (Gustin et al., 2015). 
EBOV infection causes significant impairment of the endothelial barrier function. GP 
repression of ERK2 activity reduces integrin expression and cell adherence; 
however, GP also induces endothelial cell activation, further decreasing endothelial 
barrier functions (Wahl-Jensen et al., 2005). During EBOV infection of endothelial 
cells, cell adhesion molecules (CAM) ICAM-1 and VCAM-1 were found to be 
transcriptionally upregulated, with increased cell surface expression of CAMs. The 
activity occurs with cellular GP expression as well as following the transfer of GP-




activation was not observed in the absence of GP, nor with the GP transcriptional 
variant sGP or the GP cleavage product Δ-peptide (Wahl-Jensen et al., 2005). GP-
induced endothelial cell activation may facilitate decreased barrier function whilst the 
upregulation of CAMs may facilitate adhesion and subsequent infection of immune 
cells, such as macrophages. A model was proposed whereby activated endothelial 
cells results in increased leukocyte recruitment, resulting in thrombomodulin release 
resulting in an activated, leukocyte rich endothelium in a procoagulant state (McElroy 
et al., 2014). Whether this is an unintended consequence of GP or has a role in 
increased viral spread and infectivity is yet to be investigated.  
EBOV GP has also been implicated in modulation of the host immune system. GP 
on the cell plasma membrane has been shown to be cleaved by tumour necrosis 
factor α-converting enzyme (TACE), resulting in the release of a soluble cleaved 
product called shed GP that is missing the transmembrane domain (Dolnik et al., 
2004). Shed GP was seen to activate uninfected macrophages and dendritic cells, 
resulting in the production of multiple pro- and anti-inflammatory cytokines, including  
TNF-α with subsequent effects on vascular permeability (Escudero-Pérez et al., 
2014). It is thought that shed GP activates macrophages by binding to and activating 
TLR4 in a manner requiring GP glycosylation. Recently it was also shown that full-
length GP on VLPs can also trigger the activation of TLR4 in macrophages, resulting 
in a similar activation phenotype (Olejnik et al., 2017). In contrast, GP binding to 
TLR4 on T lymphocytes directly triggers cell death through an upregulation of 
caspase 9, even in the absence of infection (Iampietro et al., 2017). In dendritic cells, 
GP was found to interact with the liver and lymph node sinusoidal endothelial cell C-
type lectin (LSECtin), a C-type lectin, which contains two amino acids residues 
Asn256 and Asn274 that bind GP in a Ca2+ dependant manner, triggering the 
activation of spleen tyrosine kinase (Syk) signalling and the production of 
inflammatory cytokines TNF-α and Interleukin-6 (IL-6) (Zhao et al., 2016). As shed 
GP retains most of the structure of full-length GP, this soluble molecule is capable 
of binding to and neutralizing circulating anti-GP antibodies, facilitating viral immune 
evasion (Dolnik et al., 2004). 
Similarly, sGP has been implicated in evading the immune system via antigenic 




sGP biased B-cell response toward epitopes that were shared between sGP and 
GP, reducing GP-specific antibody production and possibly impeding the immune-
mediated clearance of EBOV infection. The structure of sGP in complex with 
antibodies was recently solved and highlights differences in antibody reactivity 
between GP and sGP (Pallesen et al., 2016). Whilst GP is trimeric, sGP oligomerises 
into a parallel homodimer. Cross-reactive c13C6 antibody epitopes are presented 
similarly on GP and sGP, though the authors report that one c13C6 antibody binds 
to one GP trimer whereas multiple different immune-complexes were formed with 
sGP, ranging from rectangular complexes with a 2:2 ratio of c13C6 antibody to sGP 
dimer up to pentagonal 5:5 antibody:sGP complexes (Pallesen et al., 2016). This 
further supports the hypothesis that sGP enhances viral immune evasion by biasing 
the antibody response toward sGP binding.  
Whilst the multitude of GP secondary effects have a significant impact on EBOV 
infection, pathogenesis and immune evasion, GP remains the immunodominant 
protein on the EBOV virion and vaccination with the GP protein on pseudotyped 
viruses, rVSV-ZEBOV, has been highly effective in preventing EVD (Henao-
Restrepo et al., 2016). 
 
1.2.6 Nucleoprotein and L-polymerase* 
NP has a distinct function in the replication cycle in such that it is a key component 
of the viral ribonucleoprotein complex and has critical roles in protecting viral RNA 
from degradation and in mediating genome encapsidation during virus assembly 
(Baseler et al., 2017). At present, all research has focused on these primary activities 
of NP and any secondary roles remain to be determined (Huang et al., 2002; 
Watanabe, Noda and Kawaoka, 2006; Kirchdoerfer et al., 2015). Similarly, the RNA 
dependent L-polymerase is an essential component of the (RdRp) complex and 
required for viral genome transcription and replication (Baseler et al., 2017). It has 
been observed that L can also edit mRNA, as seen with the GP gene, where L-
editing results in the production of the GP transcript instead of sGP (Volchkov et al., 
1995). L-editing may also regulate the different expression levels of GP, sGP and 




uridine (U) residue to a site consisting of 7 U’s in the GP gene, changing the 
expression ratio of GP:sGP to 80:20. A single passage in guinea pigs caused 
reversion of the genome back to 7 U’s and changed the GP:sGP expression ratio 
back to 20:80, which may facilitate immune evasion during in vivo replication 
(Volchkova et al., 2011). In contrast, during viral replication in the human 
hepatocarcinoma cell line (Huh7) a 9U variant was seen that retained the high level 
expression of sGP but had enhanced expression of ssGP (Mehedi et al., 2011). It is 
speculated that these rapid alterations in the GP gene may act as a regulatory 
mechanism, enabling efficient virus replication in different host environments. At 
present, no other roles for the L protein have been postulated. 
 
1.3 Viral Entry, Replication and Egress 
1.3.1 Attachment and Entry 
Attachment to cellular membranes largely revolves around interactions with EBOV 
GP, exposed on the virion membrane, and virion lipid binding to phosphatidylserine 
receptors. GP contains O- and N-linked glycans which allows binding to several 
carbohydrate-binding receptors on the cell surface such as C-type lectins DC-SIGN, 
L-SIGN, LSECTin, and hMGL (Alvarez et al., 2002; Takada et al., 2004; Gramberg 
et al., 2005). These C-type lectin receptors are present on various cells, resulting in 
broad cell tropism for the virus. Furthermore, GP has been shown to bind to 
glycosaminoglycans exposed on the cell membrane surface, further facilitating virion 
attachment to the cell membrane (O’Hearn et al., 2015). The presence of these 
receptors interacting with GP are known for viral attachment, however cells lacking 
expression of glycan receptors are still susceptible to viral infection, therefore 
implicating that other receptors are crucial for viral attachment and internalisation 
(Davey et al., 2017). The virion leaflet contains phosphatidylserine residues which 
interact with TIM receptors as they possess an immunoglobulin variable-like domain 
that contains a phosphatidylserine binding pocket (Moller-Tank et al., 2013). In 
addition, TAM receptors complexed with Gas6 and Protein S allow binding to 





 The mechanism regarding EBOV internalisation has been heavily researched. 
Current data has implicated macropinocytosis as the main mechanism for virion 
entry in a GP dependent manner. Upon GP binding to receptors, activation of cellular 
actin modulators such as PI3K, small GTPase, PKC and Pak1 occur, resulting in 
actin rearrangement, a positive marker for macropinocytosis (Nanbo et al., 2010). 
This leads to cellular membrane ruffling on the periphery of where the virion is bound, 
which ultimately results in a wave-like mechanism engulfing the particle in a 
macropinosome [Figure 7]. EBOV virions were found to co-localise with SNX5, a 
family of membrane proteins associated with macropinosomes (Nanbo et al., 2010). 
Further evidence to support macropinocytosis mediated entry is that inhibitors of 





Upon internalisation, EBOV is trafficked via the endosomal pathway, leading to 
acidified Rab7+ compartments (Saeed et al., 2010). A drop in pH activates proteolytic 
activity of cathepsin B and cathepsin L, resulting in cleavage of the GP1,2 protein, 
yielding a cleaved GP (GPcl) containing a 18kD subunit of GP1 with exposed 
residues increasing receptor binding capability and ultimately enhancing infectivity  
Figure 7. Schematic representation of EBOV entry and trafficking.  
EBOV GP binds to various C-type lectins and glycosaminoglycans whereas 
phosphatidylserine exposed on the virion membrane binds to TIM receptors, 
anchoring it to the membrane. Activation of actin modulators result in 
macropinocytosis. As pH drops, cysteine proteases cleave GP, exposing binding 
pockets to NPC1. It is hypothesised that further modification of GP exposes a 
membrane fusion loop in GP2, resulting in fusion to the endosomal membrane and 




(Chandran et al., 2005) (Kaletsky, Simmons and Bates, 2007). The GP1 subunit then 
binds to NPC-1 receptors which is required for viral membrane fusion in endosomes 
(Carette et al., 2011; Spence et al., 2016). How membrane fusion occurs remains 
poorly understood. It is hypothesised that cleavage of the GP1 from GPcl induces 
further conformational changes that may expose an internal fusion loop in GP2 
required for membrane fusion (Davey et al., 2017). Furthermore, it appears that the 
fusion event is independent of low pH (Markosyan et al., 2016).The mechanisms by 
which GP2 interacts with the lipid membrane of the endosomes revolves around 
rearrangement of three N-terminal heptad repeats, allowing protrusion of a 
hydrophobic coiled-coil that fuses to the membrane (Gregory et al., 2011). After 
fusion, the virus delivers its contents through the pore in the endosome. 
 
1.3.2 Replication and Assembly 
Replication and transcription occurs at the ribonucleoprotein (RNP) complex, which 
is believed to comprise of NP, VP30, VP35 and L (Groseth et al., 2009). The RNP is 
released from the virion and acts as a template for the synthesis of its 
complementary positive-sense RNA, called the antigenome. The antigenome then 
acts as a template in order to generate new viral genomes. The minimal EBOV 
proteins in the RNP required for this are NP, the polymerase cofactor VP35 and L 
(Mühlberger, 2007). Viral replication occurs inside inclusion bodies and as infection 
progresses, these structures move from perinuclear regions towards the cell 
membrane, diminishing in size, suggesting nucleocapsids are on route to sites of 
viral budding (Hoenen et al., 2012).  
Transcription of the EBOV genome starts from the ‘3 end and is terminated and 
reinitiated at each transcription stop and start signals between the genes 
(Mühlberger, 2007). Transcription is regulated by VP30 at a very early stage and is 
regulated by a RNA stem loop structure in the first gene (Weik et al., 2002). The L 
polymerase binds to the polymerase binding site at the ‘3 end of the genome, reads 
the sequence, stops and reinitiates at each gene junction (Whelan, Barr and Wertz, 




between reads, upstream genes are highly expressed (NP) whereas downstream 
genes are lowly expressed. 
It is hypothesised that regulation between replication and transcription is owed to 
dynamic phosphorylation of VP30. Since VP30 is known to stabilise the VP35-L RNA 
binding, phosphorylation states modulate the conformation of the RNP, resulting in 
either a transcriptase or replicase complex (Biedenkopf et al., 2013).  
 
Assembly occurs after the production of viral proteins from monocistronic mRNA by 
host ribosomes. As the viral proteins are generated in the cytosol they get trafficked 
to the cell membrane to assemble into virions. This trafficking occurs by VP40 
hijacking the ESCRT pathway,  For full length GP synthesis, the correct mRNA 
transcripts have to be generated by by transcriptional editing into the 8A transcript 
(Sanchez et al., 1996). GP is synthesised and undergoes heavy modifications 
beginning in the endoplasmic reticulum. The precursor GP (GP0) is cleaved in the 
Figure 8. Replication, Assembly and Egress 
As the viral contents are delivered into the cytoplasm, transcription of viral mRNA 
by the ribonucleoprotein complex occurs inside inclusion bodies. The glycoprotein 
undergoes a series of post translational modifications as it travels through the 
endoplasmic reticulum and golgi body, culminating in its’ transport to the plasma 
membrane, where VP40 is also present. When the nucleocapsids are transported 





endoplasmic reticulum and heavily glycosylated. At the trans golgi GP is cleaved by 
protease furin yielding a GP1 and GP2 subunit (Volchkov et al., 1998). Post cleavage 
the fragments are then connected together by a disulphide bridge yielding the GP1,2 
protein (Malashkevich et al., 1999). This then undergoes trimerization, through the 
coiled coil repeats in GP2, yielding the classical spiked GP trimer that is then 
trafficked to the cell membrane alongside membrane bound VP40. The 
nucleocapsids formed in inclusion bodies comprising of NP repeats with viral RNA, 
facilitated in their formation by VP35 and VP24, meet near membrane bound GP 
and VP40 (Noda et al., 2005). VP24 also regulates RNA synthesis by binding to the 
RNP, altering conformation of the RNP, resulting in a switch between replication 
competent complex to a rigid form ready for packaging into virions (Banadyga et al., 
2017). 
1.3.3 Budding and Egress 
EBOV filaments have been shown to bud in two distinct modes. Many reports have 
shown budding to occur vertically, driven by VP40. However, another mode of 
budding results in horizontal egress and it appears that only one mode of budding 
occurs per cell, never both (Noda et al., 2006). This mode of horizontal budding 
appears to occur for mature virions containing nucleocapsids, whereas VLPs without 
the nucleocapsid bud vertically. Its postulated that this occurs because the 
nucleocapsid structures interact with VP40 that is already present on the cell 
membrane, thus being anchored under the membrane horizontally (Noda et al., 
2006). The alteration of membrane dynamics for budding and egress are caused by 
VP40, resulting in a negative membrane curvature (R. V. Stahelin, 2014). Eventually, 
this leads to viral particles being pushed out of the membrane and into the 
extracellular environment [Figure 8]. 
 
1.4 Pathogenesis 
1.4.1 Dysregulation of the Immune Response 
Ebola virus can enter a host via mucosal surfaces as well as breaks and abrasions 




whereby infection remains sustained (Geisbert et al., 2003). Macrophages and 
monocytes possess fusion factors that allow GP-mediated attachment and entry of 
EBOV such as cathepsins, NPC1 receptors, ICAMs and phosphatidylserine 
residues. Viral spreading in the host is highly contributed by monocytes, 
macrophages and dendritic cells as these cells migrate via the lymphatic systems, 
reaching several organs such as the liver and spleen. Interestingly, infection of 
dendritic cells resulted in little cell death over 6 days of infection, which may 
contribute to its dissemination (Mahanty et al., 2003). It is believed that the early 
targeting of the innate immune system cells contributes to immunosuppression, a 
characteristic of EBOV infection (Bray and Geisbert, 2005). However, macrophage 
targeting unleashes a robust cytokine and chemokine response which is considered 
to be a lethal aspect of EVD. High levels of TNF-α, IL-6β, reactive oxygen species 
and nitrogen radicals have been associated with fatal cases. Furthermore, the 
cytokine and chemokine response also contributes to viral dissemination as their 
activation recruits myeloid cells to multiple sites of inflammation, allowing the virus 
to sustain its infection (Zampieri, Sullivan and Nabel, 2007). Infection of dendritic 
cells also prevents their maturation, resulting in impaired T-cell proliferation (Jin et 
al., 2010). A massive decrease in lymphocytes during infection is likely due to 
triggering of apoptosis, of which several mechanisms may be responsible, such as 
EBOV GP interacting with TLR4, and exosomes containing VP40 (Pleet et al., 2016; 
Iampietro et al., 2017). A variant of GP that is cleaved by cellular metalloprotease 
TACE enzyme referred to as cleaved GP activates dendritic cells and macrophages  
that are not infected with the virus via TLR4 receptor stimulation, resulting in 
activation of pro and anti-inflammatory cytokines (Escudero-Pérez et al., 2014). This 
contributes to the dysregulation of the inflammatory response, which ultimately 
contributes to pathogenicity. 
 
1.4.2 Inhibition of the Interferon Response 
 
Upon infection, VP35 blocks interferon production by binding to dsRNA that would 




can also block interferon responses by disrupting the RIG-I signalling pathway by 
directly binding to kinases IKKε and TBK-1, involved in the activation of IFN-β 
signalling pathway. VP35 binding to these kinases prevents phosphorylation of IRF-
3 and IRF-7 (Prins, Cárdenas and Basler, 2009). Whilst VP35 is preventing 
endogenous antiviral signalling, VP24 interacts with several proteins that render the 
cell to be silent upon stimulation by interferons. VP24 binds to importins such as 
KPNA1, 5 and, 6, which during normal interferon receptor stimulation, would import 
STAT1 to the nucleus to activate interferon stimulating genes. However, by binding 
to importins, nuclear import of phosphorylated STAT1 is now blocked, and evidence 
has also shown that VP24 may directly bind to STAT1, preventing phosphorylation 
altogether (Reid et al., 2006; Zhang, Bornholdt, et al., 2012). This results in 
inactivation of the interferon-α/β and interferon-γ signalling. Consequently, the virus 
is able to disseminate with little hindrance from antiviral defences as the immune 
response is unable to activate in a sufficient manner to combat the virus.  
 
1.4.3  Pathogenesis in non-immune system cells 
Several proteins of Ebola virus have been implicated in pathogenesis on endothelial 
and epithelial cells. GP contributes to cellular detachment of endothelial cells by 
downregulation of adhesion molecules such as integrins, leading to cell rounding 
and ultimately death by anoikis, a form of apoptosis characterised by loss of 
adhesion (Simmons et al., 2002; Ray et al., 2004). In addition, GP present on virus-
like particles have been shown to decrease the endothelial barrier function, due to 
reduced intercellular adhesions, which results in increased extravasation of water 
and macromolecules. (Wahl-Jensen et al., 2005). This manifests as the 
haemorrhagic symptom of EVD and facilitates spread of the virus within the 
organism and transmission between organisms. Remarkably, Reston virus infection 






1.5 Reston, The Forgotten Ebolavirus 
 
This section contains our published review in unedited form (Cantoni et al., 2016). 
The figure legends have been renumbered for the purpose of this thesis 
 
1.5.1 Abstract 
Out of the five members of the Ebolavirus family, four cause life-threatening disease 
whereas the fifth, Reston virus (RESTV), is non-pathogenic in humans. The reasons 
for this discrepancy remain unclear. In this review, we analyse the currently available 
information to provide a state-of-the-art summary of the factors that determine the 
human pathogenicity of Ebolaviruses. RESTV causes sporadic infections in 
cynomolgus monkeys and is found in domestic pigs throughout the Philippines and 
China. Phylogenetic analyses revealed that RESTV is most related to the Sudan 
virus (SUDV), which causes high mortality in humans. Amino acid differences 
between RESTV and the other Ebolaviruses are found in all nine Ebolavirus proteins, 
though no one residue appears sufficient to confer pathogenicity. Changes in the 
glycoprotein (GP) contribute to differences in Ebolavirus pathogenicity but are not 
sufficient to confer pathogenicity on its own. Similarly, differences in VP24 and VP35 
affect viral immune evasion and are associated with changes in human 
pathogenicity. A recent in silico analysis systematically determined the functional 
consequences of sequence variations between RESTV and human-pathogenic 
Ebolaviruses. Multiple positions in VP24 were differently conserved between RESTV 
and the other Ebolaviruses and may alter human pathogenicity. In conclusion, the 
factors that determine the pathogenicity of Ebolaviruses in humans remain 
insufficiently understood. An improved understanding of these pathogenicity-
determining factors is of crucial importance for disease prevention and for the early 






The recent Ebola virus (EBOV) outbreak in West Africa changed our perception of 
the global threat posed by the Ebolaviruses. The outbreak was of unprecedented 
size, resulting in 28,657 confirmed cases and 11,325 deaths (as of 8/5/2016 - 
www.who.int), with several reported deaths on other continents (CDC, 2016). 
Previous Ebolavirus outbreaks ranged from a very few infected individuals to a few 
hundred cases (Georges et al., 1999). During this outbreak, evidence has emerged 
that Ebola viruses were able to persist and remain infective in immune-privileged 
sites in the body (including the eye, semen, vaginal fluid and breast milk), for over 6 
months after disease resolution and clearance of the virus from the bloodstream, 
significantly complicating disease containment and control (Deen et al., 2015; 
Varkey et al., 2015). The combination of these factors (outbreak size and virus 
persistence) raises significant concern for the danger posed by future outbreaks. 
Advancing our understanding of Ebolaviruses is extremely important in order to 
ensure adequate surveillance and outbreak containment; however, much remains 
unknown about the mechanisms by which these viruses cause disease. 
Ebolaviruses are filo (filamentous) -viruses with a single-stranded negative-sense 
RNA genome. The Ebolavirus family consists of five species:  Zaire ebolavirus (type 
virus: Ebola virus, EBOV), Sudan ebolavirus (type virus: Sudan virus, SUDV), Tai 
Forest ebolavirus (type virus: Tai Forest virus, TAFV) and Bundibugyo ebolavirus 
(type virus: Bundibugyo virus, BDBV), and Reston ebolavirus (type virus: Reston 
virus, RESTV). EBOV, SUDV, TAFV, and BDBV cause severe haemorrhagic 
disease in humans with mortality rates ranging from 50% to 90% (Geisbert and 
Hensley, 2004; Kuhn et al., 2010). RESTV is mildly virulent in pigs, avirulent in 
humans, but lethal in several but not all non-human primates, for example, African 
green monkeys (Chlorocebus aethiops) and baboons (Papio hamadryas) are 
resistant to RESTV, the latter showing resistance to EBOV as well (Rollin et al., 
1999; Barrette et al., 2009; Bente et al., 2009; Marsh et al., 2011). In addition, 
RESTV is less virulent when directly compared to EBOV infections in non-human 
primates as RESTV was observed to have a slower onset of disease and viraemia 




severity of disease, as a simian haemorrhagic fever virus coinfection with RESTV 
was detected in at least one of the non-human primates in RESTV outbreaks, which 
resulted in death (Dalgard et al., 1992). Since current knowledge cannot elucidate 
the reason for RESTV being avirulent in humans means that it remains classified as 
a BSL-4 pathogen, as it may have pathogenic potential if ideal conditions are met, 
such as viral load, route of infection or other factors. The Ebolavirus genome is 
approximately 19 kb in length and encodes nine proteins: nucleoprotein (NP), 
glycoprotein (GP), soluble GP (sGP), small soluble GP (ssGP), RNA-dependant 
RNA polymerase (L), and structural proteins VP24, VP30, VP35, and VP40, many 
of which are associated with viral pathogenicity (Ikegami et al., 2001; Feldmann and 
Geisbert, 2011; de La Vega et al., 2015). Whilst the four human-pathogenic 
Ebolavirus species are all found in Africa, RESTV is known to be endemic in the 
Philippines and China. This makes RESTV the only Ebolavirus known to exist 
outside of Africa to date. RESTV was discovered by electron microscopic 
examination of infected cells during the 1989 epizootic outbreak in cynomolgus 
monkeys that had been imported from the Philippines into the United States and 
housed at a research facility in Reston, Virginia (Geisbert and Jahrling, 1990). The 
monkeys displayed the hallmark symptoms of Ebolavirus disease, including 
subcutaneous haemorrhaging, bloody diarrhoea, and sudden onset of anorexia 
(Dalgard et al., 1992). In contrast, four handlers in the United States who became 
infected with RESTV did not show any signs or symptoms of illness, nor did the 
seropositive handlers at the Laguna export facility in the Philippines (CDC, 1990). 
Since then, several known minor outbreaks of RESTV have occurred in monkeys 
[Figure 9]: a subsequent outbreak in 1990 in Reston, Virginia, whereby four handlers 




imported from the same facility in the Philippines that caused the 1989 outbreak; a 
1996 outbreak in Alice, Texas, at the Texas Primate Centre; and two outbreaks in 
1996 and 2015 in the Philippines (Geisbert and Jahrling, 1990; Dalgard et al., 1992). 
In 2008, RESTV was found in farmed pigs in Manila, the Philippines (Barrette et al., 
2009)[Table 2]. Six handling personnel were found to be seropositive for RESTV, 
suggesting RESTV transmission from pigs to humans. Interestingly, RESTV was 
Figure 9. Detection of Reston Ebolavirus and Seropositive Evidence 
This map shows that the virus, or seropositive evidence suggestive of virus 
infection, is more widely distributed that was previously thought (Rollin et al., 1999; 
Yuan et al., 2012; Olival et al., 2013; Pan et al., 2014). The distribution of RESTV 
appears to be in close proximity to the equator, similar to the other Ebolaviruses in 




only found in sick pigs that were also infected with porcine reproductive and 
respiratory syndrome virus (PRRSV), although histological analysis did not reveal 
colocalization of the two viruses in any body site. Whether RESTV contributed to the 
manifested symptoms remains to be determined (Marsh et al., 2011). The viral 
genome sequences isolated from pigs in 2008 exhibited a 2.5% mean difference in 
nucleotide identity from the 1989 Reston monkey isolate. Three RESTV samples 
recently taken from infected pigs at different geographical locations in the Philippines 
 
 
LOCATION YEAR ORGANISM NO. OF SEROPOSITIVE 
HUMANS 
PHILIPPINES 1989-90 Cynomolgus monkeys 3 
USA, VA AND PA 1989-90 Cynomolgus monkeys 0 
USA, TX 1989-90 Cynomolgus monkeys 4 
ITALY 1992-93 Cynomolgus monkeys 0 
USA, TX 1996 Cynomolgus monkeys 0 
PHILIPPINES 1996 Cynomolgus monkeys 1 
PHILIPPINES 2008 Pigs 6 
CHINA 2011 Pigs 0 
PHILIPPINES 2015 Cynomolgus monkeys 0 
 
 
   
 
 
PHILIPPINES 2008-2009 Fruit Bats  - 
CHINA 2006-2009 Fruit Bats  - 
BANGLADESH 2010-2011 Fruit Bats  - 
 
Locations with seropositive evidence only 
Reston outbreaks 
Table 2. Outbreaks of Reston ebolavirus 
(Jahrling et al., 1990; Hayes et al., 1992; Rollin et al., 1999; Barrette et al., 2009; 
Yuan et al., 2012). The 1989 paper reports high mortality rates in the cynomolgus 
monkeys, whereas the infected pigs were found to be co-infected with PRRSV. The 
fact that there is additional seroevidence from countries further away from the 
Philippines strongly suggests migration of RESTV. No human handlers were 





(Panganisan and Bulacan) showed even greater divergence from each other, with a 
3.93% mean difference in nucleotide identity (Barrette et al., 2009). It was suggested 
that the reason for this genetic diversity could result from both monkeys and pigs 
being infected from different unidentified reservoirs (Barrette et al., 2009). In 2012, 
RESTV was again detected in pigs with PRRSV, this time in China, with 96.1%-
98.9% sequence similarity to previous pig and monkey isolates from the Philippines 
(Pan et al., 2014). 
Despite the fact that the first known RESTV outbreak occurred almost 30 years ago, 
there is still relatively little known about this virus. This includes the natural reservoir 
for RESTV, the route of transmission from this reservoir to pigs and monkeys, and 
the reasons underlying its lack of pathogenicity in humans. Due to its similarity to the 
other four Ebolaviruses, there is a concern that RESTV could mutate to become 
pathogenic in humans, and that this Ebolavirus could then spread easily around the 
world through imported livestock or other animal hosts. In this review, we will discuss 
potential reservoirs for RESTV, its genetic relationship to other Ebolaviruses, and 
the molecular basis for its lack of pathogenicity in humans. We will also speculate 
on the potential risk of RESTV to human health and how this can be addressed. 
1.5.3 RESTV Hosts and Reservoirs  
Circulation of RESTV in reservoir species and other hosts may increase the 
probability that human-pathogenic RESTV variants emerge, in particular if selective 
pressures exerted by different hosts causes viral mutation or if the host range results 
in more frequent contact with humans. To date, it is known that RESTV can infect 
humans, monkeys, and pigs. However, it is often suggested that there are reservoirs 
for this virus that have not yet been identified (Barrette et al., 2009; Yuan et al., 
2012). Bats are the most commonly implicated reservoir for filoviruses (Leroy et al., 
2005; Towner et al., 2007; Negredo et al., 2011). In 2008-2009 Rousettus 
amplexicaudatus fruit bats possessing RESTV-specific IgG antibodies were 
captured from the Philippine forests of Diliman and Cuezon, located within 60km 
from the Bulacan farm where RESTV-infected monkeys were identified in 2008 
(Taniguchi et al., 2011). R. amplexicaudatus are genetically similar to R. aegyptiacus 




Watanabe S, Masangkay JS, Omatsu T, Ikegami T, Alviola P, no date). In addition, 
RESTV as well as EBOV antibodies have been found in Bangladesh and in China in 
the related R. leschenaultia species of bats, suggesting that the Ebolaviruses may 
more widespread that previously believed. 
1.5.4 RESTV genome evolution.  
RESTV is thought to have originated in Africa and to have diverged from SUDV 
about 1400-1600 years ago before it migrated towards Asia [Figure 10.] (Sanchez, 
2001; Geisbert and Hensley, 2004; Carroll et al., 2013). The hypothesis that 
filoviruses have spread beyond the African continent was recently reinforced by the 
discovery of a new filovirus in bats in the Lloviu caves of Spain, as well as the 
Phylogenetic analysis of the Filoviridae family. 
Figure 10. Phylogenetic analysis of the Filoviridae family 
RESTV is most closely related to SUDV (Carroll et al., 2013). Bayesian coalescent 






presence of RESTV in bats, pigs and monkeys in Asia (Negredo et al., 2011; Olival 
et al., 2013; Pan et al., 2014).  
A recent phylogenetic study, analysed seven RESTV genomes, including four that 
were obtained from infected pigs (Carroll et al., 2013). Whilst in one year on the 
same farm the virus showed genetic changes of 0.079%, in different farms there was 
a divergence of up to 4.5% (Carroll et al., 2013). This study also showed that RESTV 
evolves at a rate of 8.21 × 10-4 nucleotide substitutions/site/year, similar to EBOV 
and much faster than the rate of nucleotide substitutions of SUDV, which could make 
the virus more susceptible to adaptation in humans. 
The overall selection pressures between EBOV and RESTV show that amino acids 
on the main viral antigenic determinant, GP, were under increased selective 
pressure. EBOV selection pressure was found to be 0.299 whereas RESTV showed 
0.329, whereby a ratio number >1 indicated increased selection, and <1 indicates 
decreased selection (Hurst, 2002). The EBOV GP showed selective pressure at 
mucin-domain residues 377 and 443, whereas RESTV GP was only under selective 
pressure at one glycosylated residue in the GP1 glycan cap, N229, though this 
residue was under stronger selection that any in EBOV GP (Li and Chen, 2014). 
These changes in GP may result in a different host tropism or may affect immune 
evasion, which may be a cause for concern for RESTV, though this has not been 
experimentally demonstrated. 
1.5.5 Differences that may contribute to pathogenicity 
A number of studies compared human pathogenic Ebolaviruses to RESTV in order 
to identify the underlying reasons for the observed differences in human 
pathogenicity (Reid et al., 2007; Zhang, Abelson, et al., 2012; Sandeep Chakraborty, 
Basuthkar J. Rao, Bjarni Asgeirsson, 2014). One of the proteins implicated in 
pathogenesis, VP24, acts by antagonising the host innate immune response. VP24 
binds to the karyopherins (KPNA) 1, 5, and 6, inhibiting the nuclear import of 
phosphorylated (active) STAT1 and restricting the expression of interferon-
stimulated genes (ISG) (Reid et al., 2006). VP24 was also found to reduce binding 
of the heterogeneous nuclear ribonuclear protein complex C1/C2 (hnRNP C1/C2) to 




relocating hnRNP C1/C2 from the nucleus into the cytoplasm (Shabman et al., 
2011). In viruses such as poliovirus and human papilloma virus, this relocation 
facilitates viral RNA replication and the translation of viral proteins (Gontarek et al., 
1999; Brunner et al., 2005; Shabman et al., 2011). In addition to blocking the STAT1 
pathway, VP24 may also directly bind to STAT1 to prevent its nuclear import (Zhang, 
Bornholdt, et al., 2012). EBOV VP24 may be more effective at suppressing the host 
interferon response than RESTV VP24 as EBOV-infected cells express lower levels 
of many ISGs than do RESTV-infected cells (Kash et al., 2006).  
Several amino acid differences between EBOV and RESTV VP24 may affect the 
virus’s ability to inhibit STAT1 signalling, thus affecting pathogenicity (Groseth et al., 
2002). These variant residues appear to cluster at key sites involved in VP24 binding 
to KPNAs, such as the VP24 142-146 loop. In this region RESTV displays conserved 
amino acid changes (M136L, Q139R, R140S) compared to other Ebolavirus species 
(Zhang, Abelson, et al., 2012). Changing the RESTV S140 residue to R140 modifies 
the hydrophobic moment of the protein and appears to be sufficient to enable KPNA 
binding (Sandeep Chakraborty, Basuthkar J. Rao, Bjarni Asgeirsson, 2014). These 
findings suggest that specific changes in RESTV VP24 may affect interactions with 
KPNAs, resulting in a reduced ability to inhibit interferon signalling. In 6-8-weeks old 
STAT1 knockout BALB/c mice, both EBOV and RESTV infections resulted in 
disease manifestation, causing lethargy, weight loss, and decreased survival rates 
after 6 days post infection. However, wild type BALB/c mice (6-8 weeks old) showed 
no manifestation of disease upon infection with either EBOV or RESTV (de Wit et 
al., 2011; Raymond, Bradfute and Bray, 2011). EBOV was found to be lethal only in 
new-born mice or following several rounds of adaptation, however, the comparable 
experiments have not been performed with RESTV and thus the ability of RESTV to 
adapt and cause disease in mice remains unknown (de Wit et al., 2011; Raymond, 
Bradfute and Bray, 2011). Moreover, when RESTV pathogenicity was tested in 
IFNAR-/- mice, only transient weight loss was observed between days 4-8, whereas 
EBOV showed to be uniformly lethal, with more severe symptoms, including weight 
loss, ruffled fur and hunched posture (Groseth et al., 2012). Interestingly,  IFNAR-/- 
mice challenged with RESTV became partially or completely protected from later 




infections in different knockout mouse models are dissimilar, highlighting the 
complexity of testing RESTV pathogenicity in mice. 
Bioinformatic investigation determined amino acid residues that are differently 
conserved (Specificity-Determining Positions, SDPs) between RESTV and the four 
human-pathogenic Ebolavirus species (Casari, Sander and Valencia, 1995; Rausell 
et al., 2010). Several of these SDPs were located on protein surfaces, suggesting 
their possible involvement in molecular interactions (Pappalardo et al., 2016). Whilst 
VP24 sequence identity between EBOV and RESTV is 80%, only 9 of 251 residues 
were identified as SDPs, possibly contributing to RESTV’s lack of pathogenicity in 
humans (Ikegami et al., 2001). Of the 9 SDPs found in VP24, three (T131S, M136L 
and Q139R) are located in the KPNA5 binding site. This supports the hypothesis 
that RESTV VP24 may be less effective at karyopherin binding and suppressing the 
interferon response. In addition, another SDP in RESTV VP24 results in the loss of 
hydrogen bonding between T226 and D48, potentially impacting protein stability and 
function (Pappalardo et al., 2016). However, the SDPs were not restricted to VP24 
and many SDPs were found in other protein interfaces that may affect interactions 
and stability [Table 3]. 
VP35 is an interferon antagonist that inhibits the activation of Interferon Regulatory 
Factor 3 (IRF3) following the sensing of viral RNA by the pattern recognition receptor 
RIG-I. RESTV VP35 has a 65% sequence identity with EBOV VP35 and shows 19 
SDPs (Basler et al., 2000; Cárdenas et al., 2006; Prins, Cárdenas and Basler, 2009; 
Pappalardo et al., 2016). Although, it was found that both RESTV and EBOV VP35 
molecules were able to inhibit IRF-3 activation, blocking the IRF3-dependent 
transcription of the interferon sensitive genes (ISG) 54 and 56. In addition, neither 
RESTV nor EBOV VP35 could block signalling from the IFN-α/β receptor (Basler et 
al., 2003). This implies that not all SDPs have an effect on pathogenicity; therefore, 
the consequences of these differences are not clear. 
In addition to VP24, differences in the GP protein may also affect viral pathogenesis 
(Richman, DD. Cleveland, PH. McCormick, PB. Johnson, 1983; Feldmann, H. Kiley, 
1999). EBOV GP contains a mucin-like domain that increases blood vesicle 
permeability by downregulating the expression of integrin β1 and other cell adhesion 




RESTV GP has several conserved SDPs (R325G, H354L, Q403P, S418E, T448P) 
and was found to have a significantly weaker influence in downregulating integrin β1 
expression, compared to EBOV GP (Simmons et al., 2002; Pappalardo et al., 2016). 
When examined in vivo it was seen that the presence of the RESTV GP attenuated 
EBOV pathogenicity, whereas the reverse genetics conversion of RESTV GP to 
EBOV GP was not sufficient to confer a pathogenic phenotype on RESTV, indicating 
that other proteins are involved in regulating Ebolavirus pathogenicity (Simmons et 





Protein Function % SDPs 
Nucleoprotein 




Class I viral fusion protein, responsible for 
binding and entry into host cells. Activated by 
proteolysis, creating GP1 and GP2. GP1,2 
has extensive roles in modulating the immune 
response and altering the expression of cell 
surface adhesion molecules. Cleavage of 




Possible roles in immune evasion and 
alteration of endothelial permeability. 
2.43 
ssGP Unknown role. ND 
VP24 
Secondary matrix protein, minor component of 
virions. Key player in pathogenicity, inhibits 
components of immune response. 
3.59 
VP30 
Viral nucelocapsid component. Key role in 




Polymerase cofactor in transcription and 
replication. Prevents antiviral response in cells 




Regulates viral transcription, morphogenesis, 
packaging and budding.  
2.72 
Polymerase 
Acts as a replicase and a transcriptase, 
whereby transcriptase is involved in 
subgenomic RNA capping and 
polyadenylation and the replicase function 
replicates the entire viral genome. 
2.95 
 
Table 3. Protein components of Ebolavirus and their roles 
(Sanchez et al., 1996; Han et al., 2003; Watanabe, Noda and Kawaoka, 2006; Li et al., 
2008; Lee and Saphire, 2009; Prins, Cárdenas and Basler, 2009; Silva et al., 2012). The 
percentage of SDP sites in RESTV, as compared to EBOV, may offer clues as to the lack 
of RESTV pathogenicity in humans, though higher levels of specificity determining 
positions (SDP) do not necessarily indicate a change in protein function or activity. 
Furthermore, the percentage difference is likely to fluctuate regularly due to the viral 





The functions of the two soluble and secreted Ebolavirus proteins sGP and ssGP 
remain the most elusive, with the structure of EBOV sGP only recently being solved 
(Pallesen et al., 2016). sGP shares 295 N-terminal residues with GP, thus sGP is 
thought to contribute to evasion of the humoral system by absorbing GP antibodies 
(Sanchez et al., 1996; Falzarano et al., 2006). In addition, sGP seems to play an 
anti-inflammatory role by promoting recovery of the endothelial barrier during 
Ebolavirus infection (Wahl-Jensen et al., 2005). RESTV appears to secrete more 
sGP than EBOV, suggesting that the anti-inflammatory role of sGP may have a more 
significant role on pathogenicity, considering its role on restoring the endothelial 
barrier (Wahl-Jensen et al., 2005). The size of RESTV small soluble GP (ssGP), at 
37kDa is significantly larger than that of the other Ebolaviruses (33kDa). However, 
the potential involvement of ssGP in pathogenicity remains unclear and thus the 
effect of the RESTV ssGP extension is unknown (Mahale and Patole, 2015). 
It may also be that lack of RESTV virulence in humans is due to a delay in viral 
transcription and genome replication, as RESTV was found to have slower growth 
kinetics, suggesting a growth impairment that was not observed with EBOV 
(Boehmann et al., 2005). The organisation of the RESTV genome differs from that 
of the other Ebolaviruses. Ebolaviruses contain gene overlaps between GP and 
VP30. In contrast, these two genes are separated by an intergenic region in RESTV 
(Sanchez, 2001). This change in genomic organization may affect the transcription 
of GP and VP30 or alter the efficiency of genome replication. Though, the 
relationship between EBOV gene overlap and genomic replication has not been 
tested, it is possible that the reduced efficiency of RESTV replication, combined with 
functional protein differences, could enable RESTV to infect humans without causing 
any detectable pathogenicity. 
1.5.6 Conclusions 
RESTV is unique among the Ebolaviruses in that it does not cause disease in 
humans. However, RESTV is infectious in several animal species that exist in close 
contact with humans, and humans can be asymptomatically infected with the virus, 




suggesting that further adaptation of RESTV could cause a significant risk to human 
health. 
An observed significant factor for the outbreak in West Africa was that infected bush 
meat provided a route of transmission of virus to humans (Alexander et al., 2015). 
Humans and R. leschenaultia bats in Bangladesh share a common food source; date 
palm sap, which may be a potential route for viral transmission in humans. In 
addition, the ability of pigs to become hosts to RESTV means that the virus can be 
established in the human food chain, which is a cause for concern, as prolonged 
human contact may play a role for the virus to adapt to humans. 
Furthermore, it may be the case that single amino acid substitutions in SDP sites 
can affect pathogenicity. This is concerning as many RESTV proteins had only a few 
SDPs that differed from EBOV, suggesting that a minimal number of mutations may 
be required to restore RESTV pathogenicity in humans. Thus, the investigation of 
the effects of individual SDPs is of great importance for understanding Ebola virus 
pathogenicity. 
Whilst the likelihood that RESTV will become pathogenic in humans is not clear, 
given that it can establish itself in the human food chain in densely populated areas, 
the potential risk that the virus poses to human health worldwide is significant. This 
risk is even greater when considering that because RESTV is non-pathogenic in 
humans, the only people that have been screened for RESTV infection have worked 
at monkey and pig farms undergoing RESTV outbreaks, thus, the actual prevalence 
of RESTV in human and animal populations maybe significantly greater than 
anticipated. However, in response to the recent outbreak of EBOV in West Africa, 
research in treatments have shown promising advances, in particular vaccines and 
an antibody for pan-ebolavirus therapy, which has shown to be successful in vitro 








1.6 Project outline 
During this PhD course, we sought to explore the unknown reasons regarding 
differences in pathogenicity between EBOV and RESTV. Our experiments 
compared proteins from both species with the intent to elucidate the determinants of 
human Ebolavirus pathogenicity. This thesis will present the following projects:  
 
1. Investigating cytotoxic properties of VP24 
 
This project was based on a statement made in Mateo et al. 2011 regarding 
VP24: “Our attempts to establish a cell line constitutively expressing VP24 
also failed, probably as a result of as yet undefined cytotoxic properties of this 
protein (data not shown)”. Preliminary data in the laboratory showed that 
expression of VP24 in human cells caused cytotoxicity that was different with 
EBOV and RESTV VP24 proteins. We used multiple techniques in order to 
pinpoint the cellular pathways targeted by EBOV and RESTV VP24 proteins 
and uncover the mechanisms of VP24-induced cytotoxicity. 
 
2. Solve the structure of delta-peptide. 
 
The delta peptide is a cleaved product of sGP. Current literature has shown 
that it is likely to act as a viroporin. However, no structures have yet been 
published. Given that this peptide retains an amphipathic helix, which binds 
to membranes either by full insertion or superficial interactions, we sought to 
solve the structure of the amphipathic helix and identify which residues are 
responsible for membrane interactions using NMR. Both EBOV and RESTV 
delta peptides will be compared to assess whether differences in sequence 








2 Materials and methods 
2.1 Materials 
2.1.1 General Buffer Materials and Compositions 
Deionized water and MiliQ grade water provided in house 
General Buffer 
Materials 
Company  Product 
Code 
Acetic Acid Sigma-Aldrich A6283 
Acetonitrile Fisher Scientific A/0627/17 
Agar Technical Oxoid LP0012 
Agarose Sigma-Aldrich A9539 
Alpha-cyano-4-hydroxycinnamic Acid, 97% Sigma-Aldrich 145505 
Ampicillin Sodium Salt Melford A0104 
Bacto Tryptone BD Biosciences 211705 
Bacto Yeast Extract BD Biosciences 212750 
Bovine Serum Albumin Sigma-Aldrich A2153 
Bromophenol Blue Sigma-Aldrich 114405 
cOmplete mini Protease Inhibitor Roche 04693116001 
Deuterated Acetic Acid Sigma-Aldrich 416886 
DTT Melford MB1095 
EDTA Fisher Scientific D/0700/53 
Ethanol Fisher Scientific E/06500F/17 
Formalin Sigma-Aldrich HT501128 
Glucose Fisher Scientific 10373242 
Glycerol Fisher Scientific G/0650/17 
HEPES Sigma-Aldrich H3375 
Imidazole Fisher Scientific I/0010/53 




Kanamycin Sulfate Sigma-Aldrich K4000 
L-Mimosine from Koa hoale seeds Sigma-Aldrich M0253 
Phosphate Buffered Saline Tablets Oxoid BR0014G 
phosSTOP phosphatase inhibitors Roche 04906837001 
Skimmed Milk Powder Oxoid LP0031 
Sodium Chloride Fisher Scientific S/3160/60 
Sodium Dodecyl Sulfate Fisher Scientific S/P530/53 
Staurosporine Abcam Ab120056 
Sucrose Fisher Scientific 10638403 
Tergitol (NP-40) Sigma-Aldrich NP40S 
Trifluoro Acetic Acid Sigma-Aldrich 302031 
Tris Base Fisher Scientific T/P630/60 
Tris HCL Fisher Scientific 10060390 
Triton X-100 Sigma-Aldrich T8787 
Tween-20 Sigma-Aldrich P1379 
   
General Buffers Composition  
Phosphate Buffered 
Saline 
1 tablet per 100mL dH2O  
Tris Buffered Saline 
(20x) 
pH7.4 
48g Tris Base 




TBS-T TBS 1X 
0.1% Tween-20 
 
NP-40 Lysis Buffer 1% NP-40 in TBS 1X 
1 tablet cOmplete protease Inhibitors 










2% BSA Blocking Buffer 2% (w/v) Bovine Serum Albumin 
TBS-T 
 
Laemmli Sample Buffer 
(4x) 
40% Glycerol 
240mM Tris HCL pH6.8 
8% SDS 
0.04% Bromophenol Blue 
 





   
2.1.2 Mammalian Tissue Culture Materials  
Cell lines Name Source 
HEK293T Human Embryonic Kidney  ATCC 
HeLa Human Cervical Adenocarcinoma ATCC 
MEF Mouse Embryonic Fibroblast ATCC 
   
Consumables and Reagents Source Product Code 
T-75 Culture Flasks Sarstedt 83.3911.002 
T-175 Culture Flasks Sarstedt 83.3912.002 
6 Well Plate Greiner 657160 
12 Well Plate Greiner 665180 
24 Well Plate Greiner 662102 
96 Well F Bottom Plate Greiner 655161 




Foetal Bovine Serum Good PanBiotech P40-37500 
Trypsin PanBiotech P10-0235SP 
Penicillin/Streptomycin PanBiotech P06-07100 








pCAGGS Ampicillin BEI NR-49207 
RESTV HA-
VP24 






Kanamycin Dr Zheng-Gang Liu, 
National Institute of 
Health USA 
 
RIP3-YFP pEYFP-N1 Kanamycin Dr Zheng-Gang Liu, 





mCherry Kanamycin Addgene #55102 


























2.1.4 qPCR Primers 
All primers were gifted from Tim Fenton at University of Kent. 
Primer Sequence 
Cyclin A2-F CCAGAACCTGAGCCTGTTAAA 
Cyclin A2-R CTCGACATCAACCTCTCCAATC 
Cyclin B1-F ACTTTCGCCTGAGCCTATTT 
Cyclin B1-R CTGTGGTAGAGTGCTGATCTTAG 
Cyclin D1-F CCACTCCTACGATACGCTACTA 
Cyclin D1-R CCAATCAGATGACTCTGGGAAA 
Cyclin E1-F TTTGCAGGATCCAGATGAAGAA 







Primary Antibody Supplier Species Product Code 
HA Santa Cruz Biotech Mouse Sc-7392 
Bacterial Cells for Plasmid 
Generation 
Source Product Code 






HA (HRP) Santa Cruz Biotech Mouse SC-7392 HRP 
PARP Cell Signalling Rabbit 9532 
Cleaved Caspase 3 Cell Signalling Rabbit 9661 
Caspase 7 Cell Signalling Rabbit 9492 
p21 Cell-Signalling Rabbit 2947 
β-Actin-(HRP) Sigma-Aldrich Mouse A3854 
γH2AX EMD Millipore Mouse 05-636 
    
Secondary 
Antibody 
Supplier Species Product Code 




Invitrogen Rabbit A16023 




Invitrogen Mouse A16011 




Invitrogen Mouse A21202 




Invitrogen Mouse A21207 




Invitrogen Mouse A31571 





2.1.6 Hardware and Software 
 
Hardware Application Supplier 
Accuspin Micro 17R 
Tabletop Centrifuge 
Centrifugation Fisher Scientific 
Agilent 1100 HPLC Peptide Purification Agilent 





Caspase Glo 3/7 Assays 
MTS assay 
BMG Labtech 
Function Generator Giant unilamellar vesicle 
preparation 
 
G:BOX Western Blot Imaging 
Coomassie Imaging 
Syngene 
Incucyte® Live Cell Imaging Sartorius 
LSM-880 Confocal with 
AiryScan 
Fluorescent Microscopy Zeiss 








Ultra centrifugation Beckman-Coulter 
QuantStudio® 3 Real-





Peptide Analysis Bruker 
   





2.1.7  Kits and Assays 
Software Application Suppler 
Agilent 1100 Method & 
Run 
HPLC control Agilent 
Flex Analysis MALDI-TOF analysis of peaks Bruker 
Flex Control MALDI-TOF control Bruker 
GeneSys Western Blot image 
acquisition 
Syngene 
ImageJ Image Analysis NIH (Schindelin et 
al., 2015) 
Microsoft Excel  Statistical Analysis Microscoft 
QuantStudio™ Design & 
Analysis v1.4.3 
qPCR experiment design and 
analysis 
ThermoFisher 
Zen Black Confocal Imaging Zeiss 
Zen Blue Processing raw confocal data Zeiss 
Kit/Assay Supplier Product 
Code 
Pierce™ BCA Protein Assay Kit ThermoFisher 
Scientific 
23225 
Clarity™ Western ECL Blotting Bio-Rad 1705060 
Trans-Blot® Turbo™ 5x Transfer Buffer Bio-Rad 10026938 
MTS Assay Kit Abcam Ab197010 
Fluo-4 Direct™ Thermofisher F10471 
Caspase-Glo® 3/7 Promega G8090 
Caspase-Glo® 8 Promega G8200 
Plasmid Midi Kit Qiagen 12143 




Buffers Composition  































Polyethylenimine, Linear, MW25000 Polysciences, Inc. 23966-2 
Protein Ladder 10-245 Abcam Ab116028 





RNAeasy Mini Qiagen 74106 
Criterion™ TGX™ Precast Gel Biorad 5761124 
GoScript™ Reverse Transcriptase Promega A5003 
PowerUp™ SYBR Green 2X MasterMix ThermoFisher A25742 
Peptide Calibration Standard II Bruker 222570 











M9 Media 100mL M9 Salt 
800mL ddH2O 
1mL 1M MgSO4 
1mL 0.1M CaCl2 
1mL 1M Thiamine 
10mL (100x) Trace Metal 
4g/L D-Glucose 
1g/L (15N) NH4Cl 
1mL Ampicillin stock 
 
HPLC Buffer A 0.1% TFA 
ddH2O 
 
HPLC Buffer B 0.09% TFA 
80% Acetonitrile 
 
 ddH2O  














Synthetic Peptide BioMatik  
   







2.1.9 EBOV Delta Peptide Constructs 
 
 
2.1.10 EBOV Delta Peptide Primers for PCR 
 
2.1.11 Electroformation Consumables 
Materials Supplier Product Code 
Copper Foil Sigma-Aldrich GF28915421 
Indium tin oxide coated 
glass slide 
Sigma-Aldrich 703176-10PAK 

































Sigma-Aldrich GBL 664112-50EA 
 
2.1.12 Lipidic Cubic Phase Crystallography Consumables 
Materials Supplier Product Code 
Laminex™ UV Plastic 
200-micron Film Cover 
Molecular Dimensions MD11-53-200 
Laminex™ UV Plastic 
Base 100 micron 
Molecular Dimensions MD11-51-100 
MemGold2™ HT-96 Molecular Dimensions MD1-64 






2.2.1 Plasmid Preparation 
To generate plasmid stocks, 100ng of plasmid were mixed with DH5-alpha E. Coli  
on ice for 20 minutes. Mixtures were then heat shocked at 42°C for 45 seconds then 
quickly returned to ice for 2 minutes. For plasmids containing a kanamycin resistance 
gene, an outgrowth was performed whereby cells were mixed with 1000μL of SOC 
media for 1 hour at 37°C with shaking at 200rpm to allow generation of antibiotic 
resistance. Lastly, cells were streaked on agar plates containing the appropriate 
antibiotic and plates were placed in an incubator at 37°C overnight for colony 
formation. The next day, single colonies were picked with a sterile pipette tip and 
dropped in 50mL Falcon tubes containing LB broth with the appropriate antibiotic 
resistance and incubated overnight in a shaking incubator at 200rpm, 37°C. The 
following day, the falcon tubes were centrifuged for 20 minutes at 4000G to pellet 
the bacteria, the supernatant was then removed. The pellets were then subjected a 




DNA. After elution, quantity and purity of DNA was measured using a nanodrop 
spectrophotometer.   
2.2.2 Tissue Culture 
2.2.2.1 Passaging Cells 
HeLa, HEK 293t and, Huh-7s cell were grown in DMEM supplemented with 10% 
FBS, and1% P/S. Cells were maintained at 37°C and 5% CO2. At 80% confluency 
all cells were split for passaging. For passaging, media from the flask was removed, 
cells were washed once with 5mL of warm PBS, followed by addition of 3mL of warm 
trypsin for 2-4 minutes until cells have detached. After detachment, 7mL of warm full 
DMEM was added to quench trypsin activity, and the cell suspension was placed in 
15mL Falcon tubes for centrifugation at 300G for 5 minutes. Supernatant was 
discarded and fresh DMEM was added to resuspend the cells which were then 
added in appropriate tissue culture flasks in 1:10 ratio, then returned to the incubator. 
Cells were maintained up to a maximum of 50 passages. HEK293T cells were tested 
annually for mycoplasma contamination using the MycoAlert detection kit from 
Lonza. 2mL of cells were pelleted, 100 μL of supernatant was removed and placed 
in a new tube, 100 μL of MycoAlert reagent was added to the sample and incubated 
for 5 minutes, then luminescence was measured using a plate reading luminometer. 
Then 100 μL of MycoAlert substrate was added to sample and incubated for 10 
minutes prior to taking another luminescence reading. Samples were run alongside 
a positive control supplied by the kit. The results confirmed the cells were 
mycoplasma free. HeLa and Huh-7 cells were sent for mycoplasma testing to 
Eurofins. Samples were certified mycoplasma free. 
2.2.2.2 Freezing Cells 
To generate frozen stocks of cells being used, a solution containing the media used 
for the cells with 10% DMSO was made. Stocks were made when required and 
carried out in tandem with passaging, usually during cell passage numbers 3 to 5. 
Half of the cell suspension in the falcon tube during passaging were removed and 




microscope. The cells were then pelleted at 300G in a centrifuge for 5 minutes. The 
media was removed and cells were resuspended in DMEM with 10% DMSO and 
pippeted into cryovials at a density of 1,000,000 cells per ml. Cryovials were then 
frozen at -80°C and after 48 hours transferred to liquid nitrogen vats used to store 
cells for long term periods. 
 
2.2.2.3 Thawing Cells 
Cryovials were removed from the liquid nitrogen vats and placed in a box containing 
dry ice to prevent thawing as they were brought to the laboratory. The cryovials were 
thawed rapidly in a 37°C waterbath and visually inspected every minutes to ensure 
the cells were fully thawed. Afterwards, cells in the cryovial were pipetted into a 
falcon tube containing 4mL of prewarmed media and centrifuged at 300 x G for 5 
minutes. The media was removed after centrifugation to remove DMSO and cells 
were resuspended in 5mL of fresh warm media. All of the cell suspension was 
transferred into a T-25 flask and left in the incubator at 37 °C and 5% CO2. After 24 
hours the media was replaced with fresh prewarmed media. Cells were passaged 3 
times prior to use for experiments. 
2.2.3 Transfection 
Cells were grown to 80% confluency before splitting. Upon resuspension after 
trypsinisation, cells were counted using a haemocytometer and seeded in the 
appropriate plates for next day transfection (~75% confluency). The following 
description applies to transfections in 6-well plates. The table below summarises the 
values of cell number and reagents used in smaller plates. Transfection method 
using Polyethylenimine (PEI): 2000ng of plasmid DNA and 6µL of PEI were added 
in separate Eppendorf tubes containing 125µL filter sterilised 300mM NaCl solution 
and then mixed together into one tube and incubated for 15 minutes to allow the 
DNA complexes to form using a 1:3 DNA:PEI ratio. Full DMEM (10% FBS, 1% P/S) 
was removed from the cells which were then washed in warm sterile PBS media 
prior to adding 2mL of warm DMEM containing FBS only. 250µL of DNA:PEI 




to ensure even distribution and returned to the incubator. After 4 hours of incubation, 
media was replaced, cells were washed with warm sterile PBS to remove remaining 
PEI, and pre-warmed full DMEM was added to cells to incubate for indicated time 
periods.  
Transfection method using Mirrus TransIT LT1: 2000ng of plasmid DNA was added 
to tubes containing 250µL of Opti-MEM, followed by addition of TransIT-LT1 at a 1:3 
DNA:LT1 ratio and incubated for 15 minutes to allow DNA complexes to form. The 
250µL solutions containing the DNA:LT1 complexes were then added in a dropwise 
fashion to the wells, plates were gently rocked to ensure even distribution and 
incubated for indicated time periods. 
 
 
2.2.4  Cell lysis and Protein Quantification 
6-well plates with transfected HeLa cells were removed from the incubator and 
media was aspirated, cells were washed once with 2mL of ice cold PBS and then 
lysed in 75µL of ice cold NP-40 lysis buffer (150mM NaCl, 50mM Tris pH8.0) 
containing protease and phosphatase inhibitors for 15 minutes on ice. For smaller 
plates, lysis buffer volume was scaled down appropriately. The lysate from the plates 
were pipetted into appropriately labelled Eppendorf tubes. Samples were clarified 
using a tabletop centrifuge at 4°C and 17,000 x G for 20 minutes. Supernatants were 
removed and placed into new Eppendorf tubes for downstream applications. All 
samples were subjected to BCA assay according to manufacturer’s instructions for 












12 Well 125,000 1000ng 75µL for DNA 
75µL for PEI 
125µL 
24 Well 75,000 500ng Not Used 100µL 




lysis buffer, then added in wells of a 96-well plate in triplicate fashion. Protein 
standards supplied in the kit were added to separate wells of the 96-well plate. All 
samples were then treated using 200μL of Pierce™ BCA Protein Assay Reagent A/B 
and incubated for 30 minutes at 37°C. Afterwards, plates were removed from the 
incubator and absorbance of samples were measured using the Clariostar plate 
reader. Absorbances were then corrected against the blank wells and protein 
concentration was determined by comparing the resultant absorbance value against 
the standard curve. After the BCA assay, lysates were aliquoted and stored at -20°C. 
 
2.2.5 RNA Extraction 
Plates containing treated cells were removed from the incubator and media was 
aspirated. Cells were washed once with cold PBS and RNA was extracted using 
the RNAeasy Mini kit from Qiagen according to manufacturer’s protocol. The 
optional step for DNA digestion was carried out to remove all DNA from the column 
prior to washing and eluting RNA. The concentration of RNA was determined using 
a nanodrop spectrophotometer.  
2.2.6 Gel Electrophoresis and Western Blots 
Cell lysates with known protein concentrations were mixed at a 4:1 ratio with 4x 
Laemmli buffer containing 200mM 2-mercaptoethanol and boiled at 95°C for 10 
minutes. Samples containing 25μg of protein were loaded on Criterion™ TGX™ gels 
and subjected to gel electrophoresis at 200W in the presence of tris-glycine running 
buffer. When then blue dye front reached the bottom of the gel cassette, the gel was 
removed from the cassette and proteins were transferred from the gel onto 
polyvinylidene difluoride (PVDF) membranes using a Biorad Trans-Blot Turbo 
machine according to manufacturer’s instructions. The membranes were blocked in 
5% milk and 0.1% tween in TBS (TBS-T), or 5% bovine serum albumin in TBS-T for 
phospho-specific antibodies for 1 hour at room temperature. Primary antibody 
incubations were done overnight at 4C. Secondary HRP-conjugated antibody 
incubations were carried out for 1 hour at room temperature at 1:10,000 dilution in 




by incubating membranes in Clarity™ ECL reagent (BioRad) according to 
manufacturer’s protocol; mixing the ECL reagents A and B in a 1:1 ratio, incubate 
PVDF membrane for 60 seconds in the dark and visualised using smart capture 
settings in the Gel Doc. Membranes were probed with anti-Caspase 3, anti-PARP1, 
anti-pMLKL. HRP-conjugated β-actin and anti-HA tag antibodies were used to verify 
equal gel loading and transfected protein expression. 
Primary Antibody Dilution Dilution Buffer Incubation 
Cleaved Caspase 3 1:1000 5% Milk TBS-T 4°C Overnight 
PARP-1 1:1000 5% Milk TBS-T 4°C Overnight 
Cyclin E1 1:1000 5% Milk TBS-T 4°C Overnight 
p21 1:1000 5% Milk TBS-T 4°C Overnight 
RIP3 1:1000 5% Milk TBS-T 4°C Overnight 
pMLKL 1:1000 5% BSA TBS-T 4°C Overnight 
γH2AX 1:1000 5% BSA TBS-T 4°C Overnight 
HA-Tag (HRP) 1:10,000 5% Milk TBS-T 1 Hour Room Temperature 
β-Actin (HRP) 1:10,000 5% Milk TBS-T 1 Hour Room Temperature 
 
2.2.7 Immunofluorescence Microscopy 
Glass coverslips were autoclaved and subjected to UV sterilisation for 2 hours inside 
the tissue culture hood. Cells were counted and seeded on sterilised glass coverslips 
for next day transfection at the same densities described in Transfections section. 
After indicated incubation period post transfection, cell media was aspirated and the 
coverslips were washed in ice cold PBS prior to fixation using 4% formalin. After 
fixation coverslips were incubated in PBS containing 0.1% Triton X-100 for 15 
minutes to permeabilise the cells unless otherwise stated. The coverslips were 
blocked using a buffer containing 5% BSA in TBS-T for 1 hour at room temperature. 
Primary antibodies were diluted in blocking solution and added at indicated ratios for 
either 1 hour at room temperature or overnight at 4°C. Coverslips were washed using 
TBS-T 4 times for 5 minutes on a rocker to remove non-bound antibodies. Secondary 
antibody staining was carried out using Alexa fluorophore-conjugated secondary 




followed by four washes in TBS-T at 5 minutes each, in the dark. Coverslips were 
then mounted on glass slides using ProLong™ Gold Antifade mounting media 
containing DAPI (Invitrogen). All mounted coverslips were cured overnight at room 
temperature prior to imaging using either Etaluma Lumascope-600 or Zeiss LSM-
880 confocal microscope. Images were analysed using Zen Blue software. 
Primary Antibody Dilution Dilution Buffer Incubation 
HA-tag 1:500 5% BSA TBS-T 1 Hour Room Temperature 
VDAC1 1:500 5% BSA TBS-T 1 Hour Room Temperature 






DAPI 350 470 405 MBS-405 
Alexa488 490 525 488 MBS-488 
Alexa594 590 617 594 MBS-458/561 
Alexa647 650 665 647 MBS-488/561/633 
mCherry 587 610 594 MBS-458/561 
eGFP 488 509 488 MBS-488 
 
 
2.2.8 MTS Assay 
HeLa cells were seeded at a density of 10,000 cells per well in a clear F bottom 96-
well plate for next day transfection using TransIT and 100ng of DNA per well and 
incubated at 37°C. After 24 and 48 hours post transfection, 20μL of MTS ((3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) reagent (Abcam 197010) was added to each well and returned to the 
incubator for 4 hours at 37°C. After incubation, absorbance was measured with a 
plate-reader at OD490. Blank wells were used to subtract background signal. Positive 
control wells were treated with 5μM staurosporine solution for 4 hours before 





2.2.9 Quantitative PCR 
RNA samples extracted from treated cells were converted to cDNA using the 
GoScript Reverse Transcription System (Promega) according to manufacturer’s 
protocol. Where the option in the protocol was given, we opted to use both Random 
Primer and Primer [Oligo(dT)]15. Also, we chose to add Recombinant RNAsin® 
Ribonuclease Inhibitor, another optional step in the protocol, as this would protect 
RNA from RNAase activity. 
To perform the qPCR assays, we used SYBR Green PowerUp mastermix and 
followed the manufacturer’s protocol. We carried out 10μL reactions, whereby 2 μL 
of cDNA (5ng/μL) was used. Primers for genes of interest were designed and 
purchased from Integrated DNA Technologies. Plate setup and raw data was set up 
using QuantStudio Design & Analysis software. Raw data was post processed in 
excel, where standard curves for each gene, kindly provided by members of the 
Fenton Research Group at University of Kent, were used to quantify the copy 
number of transcripts for each gene that was assayed. 
 
2.2.10 Fluo4 Direct™ Calcium Assay 
Intracellular calcium was measured using the Fluo4 Direct™ calcium assay 
according to manufacturer’s protocol. Briefly, 24 well plates were seeded with HeLa 
cells at a density of 75,000 cells and transfected with either HA-zVP24, HA-rVP24 
or empty vector control. Cells were incubated for 48 hours prior to assaying for 
intracellular calcium. After 48 hours, a 2x Fluo4 Direct™ calcium reagent was added 
directly to the well containing culture media at a 1:1 ratio. Plates were returned to 
the incubator for 30 minutes. After incubation, green intensity was monitored using 
a Lumascope-600 with a x10 lens Gain and exposure settings were kept identical 
for all conditions. Images were exported as TIFF and converted to 250bit greyscale 




2.2.11 Caspase Activity Assays 
Caspase activity was monitored using the Caspase-Glo 3/7 Assay Systems kit ® 
and Caspase-8 Glo (Promega). HeLa cells were seeded at a density of 12,000 cells 
in a black F-bottom 96-well plate for next day transfection. 48 hours post transfection, 
100μL of Caspase-Glo ® 3/7 was added to all the wells and the plate was gently 
shaken manually to ensure proper mixing. Plates were then incubated at room 
temperature for 2 hours prior to taking luminescent readings, Positive control wells 
were subjected to 2μM staurosporine for 4 hours before performing the assay. 
 
2.2.12 Autophagy Bioinformatics 
To find any LC3-interacting regions, the web resource iLIR 
(https://ilir.warwick.ac.uk/index.php) (Kalvari et al., 2014) was used using the 
following Uniprot entries in FASTA format: EBOV VP24 (Q05322), RESTV VP24 
(Q77DB4), and Influenza M2 protein (P0DOF8). The latter was used as a reference 
since M2 has been verified in-vitro in recruiting autophagy machinery (Beale et al., 
2014). Position Specific Scoring Matrices (PSSM) for each entry was tabled using 
Microsoft Excel. 
 
2.2.13 STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) Bioinformatics 
To find binding partners of proteins that interact with EBOV VP24, STRING database 
(https://string-db.org/) was used with settings allowing results to appear that have 
been verified experimentally and with high confidence score (≥0.700). Searches 
were carried out for KPNA1 and KPNA5 genes in Homo sapiens. Results were 





2.2.14 Giant Unilamellar Vesicle Formation 
GUVs were prepared by electroformation method. 26mg of Asolectin lipid pellets 
were dissolved with 1mL of chloroform in a glass tube. Chloroform was then 
evaporated in a nitrogen gas stream whilst rotating the glass tube at an angle to form 
a thin film. When the chloroform was fully evaporated lipids were resuspended in 
50mM HEPES pH 7.4 buffer containing 1mM Nile red dye to a final concentration of 
50mg/ml. 10μL of lipid mixture was placed on the conductive sides of two indium-tin 
oxide coated coverslips and evaporated in a vacuum chamber overnight. After 
complete evaporation, rubber O-rings were placed on the ITO coverslips and 70µL 
of 0.1M sucrose, 1mM HEPES buffer was added in the well, and coverslips were 
attached by bull clips to form a sealed chamber. The leads of the function generator 
were clipped onto the copper coated edges of the coverslip and the function 
generator was switched on with settings of 10Hz sine wave function, at 1.5V for 2 
hours and 30 minutes to form GUVs. Voltage was monitored using a multimeter set 
to alternating current voltage. After electroformation, the GUVs were removed using 
a wide-bore pipette and diluted 1:100 in buffer containing 0.1M glucose, 1mM 
HEPES buffer. Successful formation of GUVs was confirmed by seeding 200μL of 
GUV solution in chamber slides and visualised using confocal microscopy using a 
594nm laser with a x63 objective lens. 
 
2.2.15 Oxidation of Delta Peptides 
 
Method adapted from (J. He et al., 2017). All peptides were purchased from Biomatik 
at 95% purity. To form the disulphide bonds between the c-terminus cysteine 
residues of the delta peptides, 1mg of peptide was dissolved in 15% acetic acid and 
made up to 300µL in ddH2O. Then DMSO was added at 20% final concentration and 
tubes were incubated at room temperature overnight. To remove DMSO, samples 
were snap frozen in liquid nitrogen and lyophilised by placing the Eppendorf tubes 




chamber was vented out and samples were left overnight. The following day, the 
glass chamber was vented with air and Eppendorf tubes were removed. 
 
2.2.16 Membrane insertion of Delta-peptide in GUVs 
 
FITC tagged E23∆red, E23∆ox, R25∆red, and R25∆ox  peptides were dissolved in 
ddH2O with 20% acetic acid to 1mM at pH6.5. A multichamber slide was coated 
using 100μL of PBS containing 1% BSA for 1 hour prior. After successful coating the 
BSA solution was removed and FITC tagged z23∆red, z23∆ox, r25∆red, and r25∆ox 
peptide was mixed with GUVs in the chambers to a final concentration of 30µM and 
viewed after 15 minutes of incubation using a Zeiss LSM-880 confocal microscope 
using a Zeiss apochromat 63x objective with 488 laser, MBS-488 filter set for FITC 
excitation and 594 laser, MBS-594 filter set for Nile red excitation. Images were post-
processed to normalise brightness across the samples using Zen blue software. 
 
2.2.17 MALDI-TOF Mass Spectrometry 
Matrix-Assisted Laser Desorption/Ionization-Time of Flight mass spectrometry was 
carried out by spotting peptide samples diluted in TA30 solution (30:70 [v/v] 
acetonitrile:0.1% trifluoroacetic acid) at 1:100 on the AnchorChip target plate. The 
plate was calibrated by adding 0.5µL of Peptide Calibration Standard II solution on 
a grid spot adjacent to our experimental sample. When the spots dried on the 
AnchorChip plate, 1µL of working matrix solution (alpha-cyano-4-hydroxycinnamic 
acid in TA30) was added to both experimental peptide samples and calibration 
samples. After drying, the AnchorChip plate was inserted into the Bruker Flextreme 
MALDI-TOF. Data collection was carried out after calibrating against the Peptide 
Calibration Standard II spot and was acquired using a preset program (RP700-3500) 
on Flex Control software by the in-house technician to detect peptides up to 3500kD 






2.2.18 Gibson Assembly 
To clone the EBOV 23 amino acid C-terminus DNA fragment from the pUC57 vector 
into a pCold vector expressing 6x His tag, twin strep tag and GFP, Gibson assembly 
was carried out according to manufacturer’s protocol. Thermocycler settings for 
amplifying pCold vector were as follows: 2 minutes 95°C, followed by 30 cycles of 
45 seconds at 95°C, 30 seconds at 55°C, 11 minutes at 73°C. Final elongation step 
was 5 minutes at 73°C. For amplification of the EBOV delta peptide fragment, the 
thermocycler settings were as follows: 2 minutes 95°C, followed by 30 cycles of 45 
seconds at 95°C, 30 seconds at 55°C, 1 minutes at 73°C. Final elongation step was 
5 minutes at 73°C. The pCold amplified product was subjected to a PCR cleanup 
step, using a PCR CleanUp Kit, whereas the amplified EBOV delta peptide fragment 
was not subjected to the PCR cleanup step. Gibson Assembly was carried out by 
mixing amplified products in a 1:4 ratio between amplified vector and amplified 
fragment, to a total 0.25pmols of DNA, followed by mixing with 2X Gibson Assembly 
Mastermix and volumes were raised to 20µL per PCR tube using ddH2O. The 
thermocycler settings were set to 50°C for 15 minutes as per manufacturer’s 
protocol. After the reaction, the resulting DNA solution was transformed using 
competent cells to generate plasmid DNA to ship for sequencing. Sequence data 
returned by Eurofins confirmed successful generation of the pCold-EBOV delta 
peptide plasmid. 
2.2.19 Peptide Expression and Extraction 
BL21 competent E. coli were transformed with pCold EBOV Delta-peptide plasmid 
by mixing 100ng of plasmid DNA with 100µL of BL21 cells on ice, followed by heat 
shocking the mixture at 42°C for 45 seconds in a water bath, followed by returning 
samples on ice for 10 minutes. Samples were then streaked onto ampicillin 
(100µg/ml) treated agar plates for colony formation. The following day, a colony was 
transferred by stabbing with a sterile pipette tip to grow overnight in 50mL of LB broth 
containing 100µg/mL ampicillin in a shaking incubator at 37°C. The next day 15mL 
of the overnight growth sample was then added to 1L of LB broth and returned to 




OD600 was recorded to have an absorbance of 0.7, the 1L culture was quickly cooled 
to 15°C in ice water for 30 minutes. Then 1mL of IPTG was added to the 1L culture, 
yielding a final concentration of 1mM to induce peptide production. The 1L culture 
was returned to a shaking incubator set to 15°C and incubated overnight to allow 
peptide expression. 
 
The day after peptide expression the 1L culture was removed from the flask and 
cells were pelleted by centrifugation at 5000G. The supernatant was removed and 
cell pellets were resuspended in 50mL of lysis buffer. Cells were lysed by sonication 
on ice for 10 minutes, and debris was removed from the lysate by ultracentrifugation 
at 117734G using a Type 70i rotor for 1 hour at 4°C. The supernatant was transferred 
into appropriately labelled falcon tubes and the pellet fraction was discarded. 
 
2.2.20 Nickel Column Purification 
cOmplete™ His-Tag purification resin was loaded onto a gravity chromatography 
column to a final bed volume of 2.5ml. The column was washed by adding 4 column 
volumes (CV) of ddH2O (80ml) to remove the storage buffer containing 20% ethanol. 
Then, the column was equilibrated using 4 CV of lysis buffer. After equilibration, 4 
CV of lysate were then added to the column, and flowthroughs were collected in 
15mL falcon tubes. The resin was washed by adding 4 CV of Wash buffer containing 
5mM imidazole two times and collected in 15mL falcon tubes. To elute bound 
sample, 4CV of Elution buffer containing 400mM imidazole was added to the column 
twice and all samples were collected in 15mL falcon tubes. To check purity of 
samples, 10µL fractions from each falcon tube was subjected to gel electrophoresis 
using a Criterion™ TGX™ gel. The gel was removed from the cassette then stained 
with Coomassie blue for 4 hours at room temperature on a shaker plate and 
incubated in destain overnight to detect protein bands on the gel. 
2.2.21 Strep-tactin column Purification 
Strep-Tactin® Superflow® resin was added to a 20mL gravity chromatography 




2 column volumes (CV) of Buffer W. Lysates were then added and flowthrough was 
collected in 15mL falcon tubes. After running the lysate, the column was washed 
with Buffer W 4 times at 1 CV (20ml) per wash, with all flowthroughs collected in 
15mL falcon tubes. After washing the column to remove non-specific bound 
contaminants, the bound strep-tagged peptide was eluted using 0.5 CV of Buffer E 
4 times and collected in 15mL falcon tubes. All collections throughout the purification 
were kept on ice. To check purity of the samples, 10µL fractions from each falcon 
tube was subjected to gel electrophoresis using a Criterion™ TGX™ gel. The gel 
was removed from the gel cassette and then stained with Coomassie blue for 4 hours 
at room temperature on a shaker plate and incubated in destain overnight to detect 
protein bands on the gel. 
2.2.22 HPLC Purification 
Reverse phase HPLC was carried out on an Agilent 1100 HPLC machine. Peptide 
sample was injected into a Vydac™ Protein and Peptide C18 column and eluted 
based on a gradient increase of buffer B (1% TFA in acetonitrile) against buffer A 
(10% TFA in ddH2O). Sample elution was monitored by fluorescence at 280nm 
wavelength. Peak intensity was recorded at 35 minutes, therefore elutions at 35-38 
minutes were collected. 
2.2.23 Nuclear Magnetic Resonance 
Reduced 23 amino acid EBOV delta-peptide was dissolved in ddH2O containing 
20% deuterated acetic acid to a final concentration of 650μM and loaded into a 
Bruker Advance3 spectrometer operating at a 1H frequency of 600MHz equipped 
with a TCI-P cryo- probe. 1H -1H TOCSY experiment with excitation sculpting for 
water suppression was used with a mixing time of 60 ms, with 4096 points in the 
direct dimension and 1020 in the indirect dimension. 1H -1H NOESY experiment 
with excitation sculpting for water suppression was used with a mixing time of 




2.2.24 Lipid Cubic Phase Crystallography 
Technique performed in collaboration with Dr Jose Ortega-Roldan. Monoolein lipid 
was warmed up to 40°C and transferred into a gas-tight Hamilton syringe. Special 
care was taken to prevent formation of air bubbles. Synthetic RESTV 25aa delta 
peptide dissolved in 15% acetic acid to 20mg/mL at pH 5 was pipetted into the 
Hamilton syringe containing the prewarmed monoolein lipid to final mixture volume 
of 40μL, 40% weight:volume between lipid and peptide. The final mixture was moved 
to the very tip of the Hamilton syringe to remove residual air prior to coupling with 
another Hamilton syringe for mixing. Once the two opposing Hamilton syringes were 
successfully coupled without presence or air, the plungers were pressed to move the 
mixture into the opposite Hamilton syringe and vice-versa repeatedly to mix the 
solution until the mixture becomes transparent. Once completed, the syringe was 
attached to a Mosquito® High Throughput Screening robot. The Mosquito® robot 
was programmed to pipette 800nL volume from 96 well plates containing the 
precipitant screens for crystallisation; MemGold2™, MemGoldMeso™, onto a 96 
well plastic bases. The Mosquito® robot was also calibrated to dispense 50nL of 
lipid:peptide mixture onto the 96 well plastic bases containing the precipitants. The 
plastic bases were then covered with a plastic film cover and incubated at 18°C. 






3 Cytotoxicity of VP24 - Metabolism and Proliferation. 
3.1 Abstract 
 
Ebola virus VP24 is a protein that is involved in suppression of the interferon 
signalling pathway. However, a group has reported that failure to establish a stable 
cell line expressing VP24 was likely due to unreported cytotoxic effects. In order to 
verify whether there are cytotoxic effects displayed by VP24, we carried out simple 
assays that would give us insight into how cells are affected in response to VP24 
transfection. Using live cell imaging we detected a decrease in cell proliferation after 
24 hours post transfection. Furthermore, analysis of metabolism by MTS assay 
revealed a decrease in metabolic activity of cells transfected with VP24 between 24 
and 48 hours post transfection. Analysis by immunofluorescent microscopy showed 
a morphological change in mitochondrial architecture with cells transfected by VP24. 
Therefore, our data in this chapter confirms that VP24 does negatively affect cells, 








Due to the ambiguity of the term cytotoxicity with regards to specific pathways and 
mechanisms, we sought to verify what events were displayed by cells that express 
zVP24 protein and where possible rVP24 protein as we would need to initially 
confirm whether VP24 is cytotoxic to cells. We hope that these experiments may 
elucidate whether these cytotoxic effects are species specific, due to multiple 
potentially pathogenic-adapting amino acid mutations between EBOV and RESTV. 
After the information given to us from running these broad screens we hope to 
pinpoint the pathway by which VP24 is interfering with normal cellular function. The 
literature we gave particular attention to is a protein-protein interaction study that 
reported numerous binding partners to zVP24 by mass spectrometry (García-Dorival 
et al., 2014). Despite lack of published evidence of VP24 cytotoxicity, many binding 
targets of VP24 that were identified in the study are involved in key pathways that 
ensure cell viability and proliferation, some of which are highlighted [Table 4]. A more 
recent study (Batra et al., 2018) has also mapped the interactome of VP24, of which 
the authors stated their results matched 9 targets out of 50 found by García-Dorival 
et al., 2014. However, the majority of these binding targets have only been verified 
in high throughput mass-spectrometry with little to no follow up in the context of VP24 
interfering with pathways of the binding proteins in question. We aim to identify the 
VP24 interacting pathways and explore potential impact on cell function. 
In this chapter we describe our experiments investigating the impact of VP24 on 
overall cell metabolism, proliferation and viability, as these characteristics are very 
informative for assessing cytotoxicity. If VP24 displays a cytotoxic phenotype, it 
would be detected in these assays. This would then allow us to navigate our 






Protein Name Role Implication in 
cell death 
ATP1A1* ATPase Na+/K+ 
transporting 
subunit alpha 1 
Membrane protein, maintains 







Facilitates exchange of ions 
and metabolites across outer 
mitochondrial membrane. Also 







Facilitates exchange of ions 




COX5B Cytochrome C 
Oxidase 
Subunit 5B 
Terminal enzyme of 














Table 4. Mass Spectrometry Pull Down Data 
A selection of proteins we deemed of interest are presented in this table, based from García-
Dorival et al., 2014. Given that these proteins have functions related to cell metabolism and 
have been implicated in cell death functions (except ATP1A1), we hypothesised that VP24 
interacting with any of these proteins inside host cells may display detrimental effects. * 







3.3.1 VP24 decreases cell metabolism and proliferation 
In order to ascertain if VP24 has any effect on cell proliferation and viability, we 
monitored cell cultures in real-time using the Incucyte® live-imaging system.  HEK 
293T cells were transfected with either HA-tagged zVP24, rVP24 or empty vector. 
Plates were returned to the incubator containing the Incucyte® live imaging system 
in order to monitor cell proliferation over a 72-hour period at 37°C and 5% CO2. The 
images captured every 24 hours using a x10 lens during incubation appear to show 
reduced proliferation in both zVP24 and rVP24 cells after the 24-hour period 
whereas the mock cells showed ordinary growth day after day [Figure 11]. These 
results suggest VP24 of both EBOV and RESTV are likely to be interfering with 
cellular mechanisms resulting in a decrease of cell numbers after the 24-hour period, 
though it could not be determined from this experimental setup if this was due to 





















Following the live-cell imaging results, we decided to investigate cell viability by MTS 
assay as this would give us insight into any changes of cellular metabolism via 
colorimetric changes of the reagent. Cells were transfected with either HA-tagged 
zVP24 and rVP24 for 24 and 48 hours. At indicated timepoints the plates were 
subjected absorbance readings at optical density of 490nm in a plate reader to 
quantify the levels of formazan dye, as only metabolically active cells are able to 
Figure 11. Live cell monitoring from 24 to 72 hours post transfection.  
 
Cell confluency was monitored using Incucyte® Live cell imaging system with a x10 
in 12 well plates for 24, 48, and 72 hours post transfection using 1000ng DNA of 
zVP24, rVP24 and empty vector. Stunted cell growth and loss of typical HEK293t 
morphology was observed at from 48 hours onwards with zVP24. By comparison, 
rVP24 shows a similar, yet less pronounced, sequence of events. Empty vector 
transfection of pCAGGS shows normal and consistent rate of growth by which the 




convert the MTS tetrazolium salts into the purple formazan dye by dehydrogenase 
enzymes.  
The positive control was made by treatment of cells with 8μM staurosporine, a strong 
kinase inhibitor that induces apoptosis 4 hours prior to subjecting the plates to the 
MTS reagent. At the 24-hour incubation period there appears to be no significant 
change between zVP24, rVP24 and the empty vector transfected cells, indicating 
that VP24 has no adverse effects on cell metabolism within this incubation period 
[Figure 12]. However, at 48 hours incubation there was a statistically significant 
decrease in absorbance signal for both zVP24 and rVP24 transfected cells of 20-
25% in comparison to the mock cells. These results suggest that both zVP24 and 
rVP24 cause a decrease in metabolic activity of cells, which starts to occur only after 
24 hours post-transfection. In comparison to the results of Figure 11, the MTS assay 
showed that RESTV and EBOV have comparable impacts on cellular metabolic 
activity.  To confirm that zVP24 and rVP24 have similar expression levels, the MTS 
samples were lysed and subjected to Western blotting for the VP24 HA epitope tag 
and a β-actin loading control. Results show equal transfected protein expression 
[Figure 12].  
 
 
3-77     
Figure 12. Analysis of cell viability in VP24 transfected Hela cells.  
(A)Hela cells transfected with either HA-tagged zVP24 or rVP24 were subjected to MTS 
assay after 24 and 48 hours post transfection. Mock samples were transfected with 
empty vector. Positive controls were transfected with empty vector and treated with 
8μM staurosporine for 3 hours to induce apoptosis. Results are shown as OD from the 
plate reader. (B) Fold changes show decrease in OD at 48 hour time point. 
(C)Experiments were done in triplicate and transfections were verified by western blot 
analysis. N=3. Values were subjected to one way ANOVA statistical method. **=p value 
<0.01. T-test statistical analysis was carried out between zVP24 and rVP2 only. 
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3.3.2 VP24 alters mitochondrial morphology 
Due to MTS assay results showing differences in cellular metabolism, we chose to 
observe the mitochondrial architecture to see whether VP24 is affecting metabolism 
at the mitochondria. Seeing as mitochondrial architecture has been implicated in 
indicating cellular stress, therefore the mitochondria of HeLa cells transfected with 
HA-tagged zVP24, rVP24 or empty vector was examined by confocal microscopy. 
The mitochondrial architecture was examined by co-transfecting all samples with 
mito7-mcherry plasmid, whereby a mCherry tag is expressed on mitochondrial 
marker protein cytochrome c oxidase subunit 8A. VP24 was detected by 
immunofluorescence staining of the HA epitope tag. Cells with either zVP24 and 
rVP24 appear to show altered mitochondrial morphology [Figure 13]. The 
mitochondria seem to be punctate in structure whereas in the negative control we 
can see the characteristic tubular morphology typically associated with healthy cells. 
Due to the reported data showing VP24 binding to VDAC1 (García-Dorival et al., 
2014), we assessed whether we could see colocalization between VP24 and 
VDAC1, as this could suggest a pathway by which VP24 might be adversely affecting 
the cells. HeLa cells were transfected with HA-tagged zVP24, rVP24 or empty vector 
for 48 hours before immunofluorescent staining for HA and endogenous VDAC1 
protein. Confocal imaging of the samples suggest that both zVP24 and rVP24 co-
localise with VDAC1 in parts of the cell, predominantly the perinuclear regions 







Figure 13. Analysis of Mitochondrial architecture in VP24 transfected Hela cells.  
Hela cells were co-transfected with Mito7-mCherry and either zVP24-HA, rVP24-HA or 
empty pCAGGS vector and incubated for 48 hours. Coverslips were then stained with anti-
HA and counterstained with DAPI prior to mounting on glass slides. (A) Cells positive for 
either zVP24 and rVP24 show punctate mitochondrial morphology whereas the negative 
control shows typical tubular morphology. These findings appear more pronounced in the 






3.3.3 VP24 does not affect intracellular calcium levels 
Due to the extensive roles calcium has in cells regarding proliferation, metabolism 
and cell death, we decided to investigate whether VP24 has any effect on 
intracellular calcium we subjected transfected HeLa cells to the Fluo4 Direct™ assay 
kit which measures intracellular calcium and monitored fluorescence. HeLa cells 
were transfected with either HA-tagged zVP24, rVP24 or empty vector and incubated 
for 48 hours prior to running the assay. Both zVP24 and rVP24 do not appear to 




Anti-VDAC1 Anti-HA DAPI Merge 
Figure 14. VP24 immunostaining with VDAC1 
 
HeLa cells transfected with either zVP24 and rVP24 were grown for 48 hours prior to 
fixation. Cells were probed for VDAC1 and HA tag. The images appear to show similar 
localisation of VDAC1 and VP24, suggesting that there may be some interaction, 
however, further experiments would need to be done to fully verify these interactions. 




to the negative control [Figure 15]. By comparison, the positive control that has cells 
treated with ionomycin, a powerful calcium inducer, showed increased fluorescent 
intensity. The western blot analysis confirmed successful transfection of both zVP24 
and rVP24 during the assay. As a result, we believe that VP24 does not induce 






Figure 15. Fluo-4 Calcium Assay. 
Cells transfected with either zVP24-HA, rVP24-HA or empty vector pCAGGS for 48 
hours prior to assaying with Fluo-4 Direct™. (A) After 48 hours Fluo4 intensity was 
measured using ImageJ. The intensities were subjected to ANOVA statistical 
analysis. N=3. There is no significant increase in levels of intracellular calcium 
between the zVP24, rVP24 and the negative control. The positive control using 5μM 
ionomycin shows high levels of intracellular calcium. (B) Live cell imaging shows 
Fluo4 fluorescence of the cells in each sample. (C) Western blots verified that the 
transfection had successfully resulted in comparable protein expression. N=3 
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3.4.1 Cell Proliferation and Viability 
 
Due to the previous inability to create a stable cell line expressing VP24 (Mateo et 
al. 2011), we decided to monitor in real time what happens to VP24 transfected cells 
incubated over a 72-hour period using the Incucyte®TM live imaging system. 
Monitoring of cellular proliferation revealed a gradual decline in cell density in both 
zVP24 and rVP24 cultures predominantly after the 48 hour time point [Figure 11]. 
The larger contrast in cell proliferation displayed at 72 hours between VP24 (z and 
r) and mock suggests that VP24 may have cytotoxic properties. Whilst live imaging 
provided us with observational evidence of changes in proliferation, we cannot 
deduce what pathways are involved.  
In order to further investigate VP24 cytotoxicity we examined cell viability by MTS 
assay as this experiment would indicate if VP24 causes cytotoxicity through 
alterations in cellular metabolic activity. The colourimetric MTS assay was derived 
from the MTT assay with a variation of the tetrazolium salts of which are soluble in 
cell culture medium, yet retains the initial principle of measuring mitochondrial 
enzymatic activity of only viable cells (Mosmann, 1983; Cory et al., 1991). Despite 
the predominant use of MTS assays to screen cells against drug compounds, 
particularly in realms of cancer research, this technique has been used to investigate 
effects of viral proteins, therefore making this assay a suitable choice to use despite 
the slightly cytotoxic effects of transfection reagents (Honda et al., 2000). In order to 
minimise any background cytotoxicity caused by transfection reagents, we used 
TransIT-LT1, known for its low toxicity. We observed significant changes of cellular 
metabolism in samples transfected with both HA-tagged zVP24 and rVP24 at 48 
hours, yet at 24 hours there appears to be no difference, highlighting temporal or 
protein level-dependent effects of VP24 [Figure 12]. Despite a stronger band 
intensity for rVP24-HA, likely due to unequal DNA concentration, it does not appear 




transcriptomic experiments have shown that VP24 differently affects immune 
response gene expression in human dendritic cells depending on the time point in 
which the analysis was carried out (Ilinykh et al., 2015). Whilst we are not specifically 
investigating the immune response of cells, we consider the underlying principle to 
be of value in that different subset of genes may be affected depending on length of 
incubation periods. Furthermore, based on the fact that the MTS compound changes 
colour in relation to mitochondrial viability, we find it interesting that we observe a 
decrease in signal upon VP24 transfection, as previous studies investigating the 
VP24 interactome by immunoprecipitation and mass spectrometry have identified 
several mitochondrial proteins (García-Dorival et al., 2014). The authors reported 
VP24 binding to proteins VDAC1 and VDAC2, both involved in metabolite regulation 
across the mitochondrial membrane. These reported interactions may offer insight 
as to where and why VP24 is causing a decrease in cell viability, especially given 
that the MTS assay is based on mitochondrial activity. However, another research 
group more recently investigated VP24 binding partners also by 
coimmunoprecipitation and mass spectrometry did not report VDAC1 nor VDAC2 as 
binding partners, though differences may be due to the experimental procedures as 
the two groups used different tags on VP24 , the former group used both N and C 
terminal GFP tags in separate experiments (27kDa) whereas the latter used 2x strep 
tag (2kDa) (Batra et al., 2018). Nonetheless the latter group identified ATP1A1 and 
ATP2A2 as VP24 binding partners, also confirmed by García-Dorival et al. 2014. 
There is some evidence whereby ATP1A1 was implicated in cytotoxicity (Takase et 
al., 2017; Zhang et al., 2018), though to assume that the MTS assay result was due 
to the VDACs or ATP1A1 interactions would be speculation.  Whilst the actual 
mechanisms in question for our reported reduction in cell viability remain to be 
elucidated, we can state that prolonged expression of VP24 in HeLa cells results in 
a decrease in cellular metabolism and viability. 
 





Using immunofluorescent microscopy techniques we observed mitochondrial 
morphology as a marker for cellular stress, given their canonical role in generating 
ATP and many other metabolites, as well as acting as calcium stores in the cell 
(Brookes et al., 2004). Morphological changes of mitochondria often occur when the 
cellular environment has been altered due to stress factors (Youle and van der Bliek, 
2012). Regulated by GTPases in the dynamin family, mitochondrial fusion or fission 
occurs as a form of quality control, where fusion rescues damaged mitochondria and 
fission is needed to create new mitochondria and under stressed conditions lead to 
apoptosis (Bleazard et al., 1999; Meeusen et al., 2006; Youle and van der Bliek, 
2012). By using Mito7-mCherry, we were able to observe the mitochondria using 
confocal microscopy in order to deduce whether there was a change in morphology 
attributed to the presence of VP24. Our data show a disturbed mitochondrial 
morphology in comparison to the mock transfected cells, which we believe supports 
our hypothesis that VP24, both EBOV and RESTV, has cytotoxic properties. 
Interestingly, we do not see any colocalization between VP24 and mitochondria, 
despite the reported presence of VDAC1 and VDAC2 on the outer mitochondrial 
membrane and the known association between VP24 and VDAC1. An explanation 
for this could be that the interactions between VDAC1, VDAC2 and, VP24 did not 
occur, as reported by Batra et al. 2018. We noticed red signal arising from the 
nucleus for Mito7-mCherry. This was due to incompatible filter sets used at the time 
of the experiments, due to a logistical issue at the time with the confocal microscope 
kit. 
We also immunostained transfected cells for endogenous VDAC1 [Figure 14]. There 
appears to be colocalization in some parts of the cell but the microscopy data is not 
sufficient to prove that VP24 is indeed interacting with VDAC1. Furthermore, VDAC1 
has also been found to localise in the plasma membrane, therefore we cannot 
differentiate whether the previously reported interactions are occurring on the 
mitochondria or in the plasma membrane.  
One of the drawbacks of assessing morphology of organelles such as mitochondria 
is that it becomes difficult to distinguish between morphologies during apoptosis and 
cell cycle regulation, as mitochondria undergo fission during the M and S phase of 




towards a singular cause for this altered morphology. Nevertheless, our results 
strongly suggest that VP24 has cytotoxic effects. 
 
3.5 Conclusion 
From the data generated in this chapter we see that VP24 has cytotoxic properties 
and may affect cellular death signalling pathways. Whilst we do see some 
colocalization with VDAC1 in the cells, this does not appear to occur at the 
mitochondrial membrane and so did not focus on this interaction with regards to 
cytotoxicity. We next sought to investigate the impact of VP24-induced cytotoxicity, 
such as cellular death activation. Therefore, we assessed VP24 activation of three 
key signalling pathways; apoptosis, necroptosis and autophagy, as they culminate 
in cell death. 
3.6 Future Work 
Due to the decrease in proliferation and metabolism as seen by the live imaging and 
MTS assays, it would be interesting to carry out further follow-up experiments. Many 
assay kits are now commercially available that would be informative to carry out, in 
this instance, an ATP assay kit could indicate whether VP24 causes decrease in 
ATP levels in cells compared to the mock. This may explain the reduced proliferation 
of cells. Furthermore, another experiment that would be interesting to carry out 
despite being more time consuming would be a metabolomics experiment by nuclear 
magnetic resonance imaging, as this would allow us to see changes in specific 
metabolites in cells transfected with VP24. Having this data can give us more insight 




4 Cytotoxicity of VP24 – Cell Death Signalling Pathways 
4.1 Abstract 
 
Observations of VP24 causing a decrease in metabolic activity and proliferation in 
the previous chapter has led us to verify whether there is any activation of cell death. 
Many cell death signalling pathways have been uncovered, such as apoptosis, one 
of the most understood forms of cell death, necroptosis, a form of violent death 
involving swelling and lysis, and, autophagic death, a new form of cell death involved 
during cellular starvation. Our immunoblots reveal an activation in caspase 8, an 
initiator of the apoptosis cascade, however no activation of key apoptotic markers; 
PARP and caspase 3. We detected by immunofluorescence localisation of MLKL 
differed in cells transfected with VP24 compared to the mock, however this did not 
lead to necrotic death. From our results collected in this chapter, we believe that 
VP24 cytotoxicity does not lead to cell death, and that other pathways are 







Programmed cell is a terminal event undertaken by cells for several biological 
processes, one of which is to eliminate cells that pose a threat, be it by pathogen 
infection or disruption of cellular processes. Currently, three main types of 
programmed cell death are known; apoptosis, necroptosis and autophagic death. 
Each mode has unique morphological characteristics and often occur in different 
situations. 
Apoptosis is one of the most understood modes of cell death. It has characteristic 
morphological features such as cell shrinkage, plasma membrane blebbing and 
fragmentation of chromosomal DNA (Kerr, Wyllie and Currie, 1972) [Figure 16]. The 
two main pathways are intrinsic apoptosis and extrinsic (receptor mediated) 
pathways, of which either pathway initiates a series of cascades between caspases, 
with the final cleavage of executioner molecules caspase 3 and caspase 7 indicating 
manifestation of apoptosis (Strasser, O’Connor and Dixit, 2002). The intrinsic 
pathway can be triggered by several factors such as oxidative stress, DNA damage 
or presence of pathogens. Markers to detect initiation of apoptosis include the 
caspases 2, 8, 9, and 10. Their activation results in cleavage of downstream 
executioner caspases 3, 6 and, 7. Other markers for apoptosis include cleavage of 
poly-ADP-ribose polymerase (PARP) by caspases, resulting in inhibition of its DNA 
repair properties.  
Necroptosis was once considered to be an accidental form of death, though 
nowadays it is widely accepted to be a programmed form of cell death. The key 
markers for activation of the pathway is phosphorylation of receptor-interacting 
serine/threonine-protein kinase 3 (RIP3) by RIP1, which both interact with mixed 
lineage kinase domain-like protein (MLKL) to form the necrosome. Following this, 
the executioner molecule MLKL becomes phosphorylated by RIP3. This leads to 
MLKL oligomerisation and subsequent transport to the membrane, acting as a pore. 
The cell cytoplasm then swells, leading to rupture of the cell [Figure 16]. This is a 
violent event that spills large amount of signalling molecules called damage-




immune system cells to the site of damage. This results in high inflammation and 
affects nearby tissues. Necroptosis can be activated by extrinsic factors such as 
TNF-α binding to its receptor, oxidative stress and DNA damage.   
Autophagic death or autosis has been subject to intense debate as this pathway was 
primarily known to be activated for cell survival (Debnath, Baehrecke and Kroemer, 
2005). This occurs by degradation of macromolecules in the cell, taking place in 
autophagosomes that fuse into lysosomes which ultimately undergo lysosomal 
degradation, releasing oxidizable substrates to be used if nutrients are sparse 
(Codogno and Meijer, 2005). In regard to cell death, most of the evidence is 
correlative with other modes of cell death as these pathways are energy intensive, 
ergo, starving the cell of metabolites which would increase autophagy. So far, it 
appears that two forms of death have been attributed to autophagy: Autosis, and 
type II autophagic cell death. Morphological features are often used to distinguish 
the two such as moderate chromatin condensation (late autosis/ not present in type 
II) and ER disappearance (autosis). However, many of these morphologies are also 
seen in apoptotic and necrotic cells thus adding fuel to the debate (Liu and Levine, 
2015). Lastly, autophagy has been shown to have both pro-viral and anti-viral 
properties for influenza and dengue viruses (Kudchodkar and Levine, 2009). 
Currently, autophagic death is morphologically defined, and conclusive evidence for 
the actual mechanism responsible for cell death by autophagy remains elusive 
(Debnath, Baehrecke and Kroemer, 2005). It is for these reasons that this mode of 
death is subject to debate. Ultimately, the principle for this form of cell death is based 
on a prolonged activation of autophagy machinery due to starvation or exposure to 
cytotoxic agents. Once exposed to these factors, phagophores form which engulfs 
material in the cell, leading to the formation of an autophagosome, of which the 
marker LC3-b is exposed on the inner membrane (Tanida, Ueno and Kominami, 
2008). Protein interactions with LC3-b occur through a LC3-interacting region (LIR) 
on the protein and are crucial for recruitment of LC3 and autophagosome maturation. 
Following this, the autophagosome fuses with lysosomes, forming the 
autolysosome, where the contained cargo is degraded by acid hydrolases. The 




of autophagy can be detected by seeing increased number of LC3 foci by 
microscopy.  
In this chapter we will explore various cell death markers in order to identify whether 
prolonged expression of VP24 leads to cell death and if so, by which pathway.   
A 
B 
Figure 16. Morphological differences between Apoptosis and 
Necroptosis 
 
This figure highlights the distinct morphological features observed from 
cell dying by apoptosis (A) or necroptosis (B). One of the key differences 
is that apoptosis leads to cell shrinkage and fragmentation, whereas 







4.3.1 VP24 does not activate intrinsic apoptosis 
To investigate whether VP24 activates cellular death pathways, we opted to assay 
for apoptosis. We initially used fluorescent assay techniques that detect several 
different apoptotic factors: caspase 3, 7 and 8 cleavage. Using a 96 well plate, HeLa 
cells were transfected with either HA-tagged zVP24, rVP24 or empty vector and 
incubated for 48 hours. The cells were then assayed using fluorescence detection 
kits Caspase-Glo 3/7 and Caspase-Glo 8. We report that Caspase-Glo 3/7 does not 
show activation of apoptotic pathway in either zVP24 and rVP24, comparable to the 
empty vector control [Figure 17 A]. However, the Caspase-Glo 8 assay revealed 
increased caspase-8 activity when compared to the empty vector control, suggesting 
that VP24 from both species cause activation of caspase 8 [Figure 17 B]. This would 
appear to tell us that the initiation of apoptosis is active, but we do not report 
execution of apoptosis. 
 
We decided to confirm the Caspase-Glo results by western blot, using antibodies 
that specifically detect cleaved forms of apoptotic execution proteins (PARP-1, 
CASP3 and CASP7). Our blots show no cleavage of any of the aforementioned 
proteins, confirming the results of fluorescent assays [Figure 18]. Furthermore, lack 
of PARP-1 cleavage confirms that apoptosis is not activated since its cleavage is 
dependent on caspases. Lastly, our confocal imaging shows no morphological 
changes of the cell nucleus, therefore it appears that VP24 does not induce 
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Figure 17. Caspase Glo Assays  
To detect activation of key apoptotic markers, cells transfected with HA-
taggedzVP24 and rVP24 and incubated for 48 hours prior to assaying with 
fluorescent assay kits Caspase-Glo 3/7 and Caspase-Glo 8. (A) Caspase Glo-3/7 
assay shows no activation of the apoptotic executioner markers caspase 3 and 7, 
therefore apoptosis does not appear to be taking place. Caspase-Glo 8 assay 
however reveals activation of caspase 8 (B), a protein known to be involved in 
regulating several pathways involving cell viability, depending on its interacting 
partners. Western blots were carried out in tandem to confirm successful 






Figure 18. Western Blot Analysis of Key Apoptosis Markers 
Cells were transfected with either HA-tagged zVP24, rVP24 and, empty vector pCAGGS 
and incubated for 24 and 48 hours prior to lysis or fixation. A western blot was carried out 
to detect any markers for apoptosis (A). Due to the lack of bands in the zVP24 and rVP24 
samples for cleaved caspase 3 and cleaved PARP, we can confirm that there is no 
activation of apoptic pathways. The nuclei of cells positive for VP24 do not show 
morphological features associated with apoptotic cells ass seen in the positive control 







4.3.2 VP24 does not activate the autophagy pathway 
As LIR domains are a well-defined mechanism for virus-manipulation of autophagy, 
we first screened for potential LIR domains in VP24 using the iLIR online database, 
which also return a position-specific scoring matrix (PSSM). The PSSM score is 
useful to ascertain the validity of a possible LIR domain, as the higher the PSSM 
score, the more genuine the LIR domains are from the screen. Results showed W-
x-x-L motif hits for both zVP24 and rVP24, suggesting that there may be LC3 
interaction sites between LC3 and VP24, despite lower position-specific scoring 
matrix (PSSM) scores compared to the canonical viral LC3-interacting protein, 
influenza M2 [Figure 19 A]. To verify the bioinformatic screening, we used 
immunofluorescent microscopy to detect whether autophagosome formation is 
occurring using an LC3 plasmid fused with GFP. Autophagic activity is monitored by 
the formation of autophagosomes, seen as green puncta in the cell cytoplasm. HeLa 
cells were co-transfected with LC3-GFP and either HA-tagged zVP24 or empty 
vector, and incubated for 48 hours prior to fixation. Cells were stained for anti-HA to 
probe for HA-tagged VP24. The positive control was generated removing full culture 
media of the LC3-GFP transfected cells and replaced with 2mL Earl’s Balanced Salt 
solution (EBSS) for 4 hours as to starve the cells and induce autophagy. Our 
confocal imaging results suggest zVP24 causes minor activation of the autophagic 
pathway as LC3-GFP retains a predominantly diffuse cytosolic localisation with only 
small occasional foci seen, in contrast to the induction of autophagy in starved cells 






Figure 19. Identification of LC3 Interacting Domains 
Screening for potential LIR domains returned several motifs in both zVP24 and rVP24, 
though the PSSM score is not as high as the Influenza M2 protein (A). HeLa cells were 
transfected withHA-tagged zVP24 and LC3-GFP for 48 hours prior to fixation for 
microscopy. zVP24 transfected cells do not show increased levels of autophagy 
compared to the mock, which represent basal autophagy levels. Cells treated with 
EBSS have numerous LC3-GFP puncta, showing strong activation of autophagy (B). 
These results show that VP24 is not causing any changes with regards to autophagy 
activity within the cells. N=3 
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4.3.3 VP24 rearranges localisation of necroptosis markers 
Another form of programmed cell death is necroptosis whereby the cells swell and 
lyse. Phosphorylation of mixed lineage kinase domain like pseudokinase (MLKL) 
allows for oligomerisation and formation of pores in the cell membrane. Using 
western blot techniques, we sought to detect any phosphorylation of MLKL in the 
presence of either zVP24 or rVP24. HeLa Cells were co-transfected with HA-tagged 
zVP24, RIP3-YFP to reconstitute the necroptotic pathway as HeLa cells do not 
express RIP3, and dsRED-MLKL for 48 hours prior to lysis and immunoblotting. The 
Western blot reveals phosphorylation of MLKL within the zVP24 cell lysate, whereas 
rVP24 and mock reveal dim signal intensity by comparison [Figure 20]. This 
suggests that zVP24 may be cytotoxic because it triggers activation of necroptotic 
programmed cell death. 
 
To confirm MLKL phosphorylation by western blot, we used fluorescent microscopy 
for assessing localisation of MLKL in zVP24 transfected cells, as MLKL localises to 
the plasma membrane upon phosphorylation and activation. Based on the MLKL 
Western blot data, only zVP24 induction of MLKL relocalisation was investigated. 
Our imaging does not show membrane localisation of MLKL in either zVP24 or mock 
treated cells [Figure 21]. However, there seems to be an increase in MLKL 
fluorescent intensity near the plasma membranes as well as the formation of MLKL 
puncta in the cytoplasm in zVP24 transfected cells whereas mock cells retain a 
diffuse level of cytoplasmic MLKL expression [Figure 21]. This suggests zVP24 in 








Figure 20. Western blot analysis of pMLKL 
HeLa cells were co-transfected using PEI with either zVP24 or rVP24, as well 
as RIPK3-YFP and dsRED-MLKL for 48 hours prior to lysis for western blot 
analysis. Membranes were probed with antibodies for pMLKL, RIP3, HA-tag 
and β-actin. The pMLKL band intensity is highest in zVP24 treated cells which 
suggests that presence of zVP24 leads to activation of the necroptosis 
pathway. The molecular weight for pMLKL is 50 kDa, though since this protein 
was overexpressed for detection, it also contains a dsRED tag (28 kDa), 
therefore the band appeared at around 78 kDa. Similarly, RIP3 (57 kDa) is not 
endogenously expressed, therefore a YFP-RIP3 expression plasmid was used,  
so the antibody band appeared at around 84 kDa. 
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Figure 21. Immunofluorescent analysis of MLKL localisation 
Assessing localisation of MLKL can give insight as to whether the cells are 
undergoing necroptosis, due to its localisation in the plasma membrane. (A) HeLa cell 
were co-transfected with HA-tagged zVP24 and dsRED-MLKL and incubated for 48 
hours prior to fixation and immunofluorescence staining for HA. The negative control 
shows a diffuse cytoplasmic localisation of MLKL. Cells positive for zVP24 show 
rearrangement of MLKL but don’t appear to have full membrane localisation around 
the cell. (B) 2.5D representation of MLKL (red) and DAPI (blue) channels taken from 
images in A highlight the increased fluorescent intensity and localisation of dsRED-
MLKL in zVP24 positive cells compared to the diffuse uniform cytoplasmic localisation 












Given that we saw a change in metabolism as seen by MTS assay [Figure 12], 
coupled with the roles of pathogen induced autophagy, we wanted to verify whether 
the autophagy pathway was responsible for VP24-mediated cytotoxicity. An initial 
screen by the online database iLIR generated predictions that would suggest the 
multiple presences of motifs that may bind to proteins of the ATG8/LC3 family. 
Noticeably, rVP24 returned 8 hits compared to the 5 from zVP24. Both zVP24 and 
rVP24 domain hits retain the W-x-x-L motif, though the scores do not appear to be 
of high confidence compared to M2, of which the LIR domain has been verified in 
vitro (Beale et al., 2014). In addition, our immunofluorescent results revealed only 
minimal increase in autophagosome formation for zVP24 as the GFP-LC3 marker 
retains a predominantly diffuse cytoplasmic localisation like the negative control, 
whereas the positive control displays the typical punctate distribution. Therefore, it 
appears likely that the VP24’s cytotoxicity is not induced by autophagic stress, 
despite possessing a minimal capacity to active autophagy. 
4.4.2 Apoptosis Pathway 
Several EBOV proteins induce host cell death, such as exosomal secreted VP40 
inducing death in bystander lymphocytes (Pleet et al., 2016). Furthermore, GP has 
been shown to induce anoikis, a form of apoptosis, resulting in downregulation of 
adherence molecules such as integrins (Ray et al., 2004). Our caspase-glo 3/7 kit 
shows no activation of apoptosis in the presence of either zVP24 or rVP24. However, 
there are many different mechanisms of apoptosis that are independent of caspase 
3 and/or caspase 7. For example, extensive DNA damage that is beyond repair can 
activate apoptosis. This can be detected by blotting for cleaved fragments of PARP-
1, a protein involved in DNA repair by adding poly (ADP ribose) polymers. If the DNA 




into smaller fragments, with each fragment being unique depending on necrotic or 
apoptotic death (Chaitanya, Alexander and Babu, 2010). During apoptosis, PARP-1 
is cleaved into a 89-kDa catalytic fragment, and a smaller 24-kDa containing a DNA-
binding domain. Our results show that PARP-1 is not being cleaved when the cells 
are incubated with VP24, whereas the positive controls show the characteristic 
fragments of PARP-1 during apoptosis. Lastly, our confocal imaging on nuclear 
morphology shows no nuclear fragmentation, therefore our data strongly suggest 
that VP24 does not induce apoptosis within a 48 hour incubation period.  
Interestingly, we see activation of Caspase-8 despite lack of caspase 3/7 cleavage. 
Caspase-8 is only considered active when present in the cleaved form. This would 
indicate that the apoptosis pathway is being initiated. However, we do not see any 
execution of apoptosis upon the cells. There are reports of active caspase 8 during 
inhibition of autophagy (Hou et al., 2010) which is interesting because we show VP24 
does not induce autophagy but unsure as to whether it inhibits autophagy. Therefore, 
if we had more time, we would need to carry out further experiments such as inducing 
autophagy in cells transfected with VP24 to see whether VP24 actually inhibits this 
pathway. We would also attempt to induce apoptosis in cell transfected with VP24 
to see if there is inhibition of apoptosis. However, we did not pursue this route at this 
moment as we felt it didn’t fit the context of the current story. 
 
4.4.3 Necroptosis Pathway 
Necroptosis is another mode of programmed cell death that is distinct from 
apoptosis. Characterised by osmotic imbalances leading to cellular swelling and 
lysis, necroptotic cell death is often considered to be a ‘violent’ type of cell death 
affecting neighbouring cells and leading to high inflammatory response. EBOV 
infection in cells have shown typical signs of necrotic cell death, such as cell swelling 
and membrane rupture (Olejnik et al., 2013), however this has yet to be 
experimentally verified by investigating the activity of key mediators involved in this 
pathway. The downstream executioner protein of this pathway is MLKL, whereby its 
phosphorylation results in oligomerisation, leading to pore formation in the 




zVP24 compared to rVP24 and the negative control. However, we also detected faint 
bands for pMLKL in rVP24 and the negative control though we believe this is due to 
cytotoxic effects likely exerted by the PEI transfection method, as reports have 
shown activation of cell death pathways in A431 cells (Kafil and Omidi, 2011). At the 
time of these experiments we were limited in our choice of reagent, as this 
experiment would have been carried out with TransIT-LT1, which is considered to 
be more gentle to the cells during transfection. Recent data also suggests that MLKL 
is involved in the ESCRT-III pathway and that limited phosphorylation of MLKL 
resulted in generation of vesicles from the ESCRT-III pathway to counteract the cell 
death pathway and sustain survival of the cells (Gong et al., 2017). Our 
immunofluorescence results appear to show a rearrangement of MLKL near the 
plasma membrane in zVP24 expressing cells. However, we did not detect full plasma 
membrane localisation as has been reported previously for MLKL activation (Cai et 
al., 2014). Therefore, it is not possible to state if the presence of zVP24 is cytotoxic 
because of the activation of necroptosis but it is possible that a longer incubation 
period may have resulted in full membrane insertion. Using a longer incubation 
period with transfected cells however may cause more noise in the results, due to 
the harshness of transfection, therefore we did not attempt to assay for results past 
48 hours. Unfortunately, most cancer cell lines do not express RIP3 due to silencing 
by genomic methylation at its transcriptional start site (Koo et al., 2015), and our 
attempts to establish a fully reconstituted necroptosis pathway by transfecting cells 
with RIP3-YFP led to high amounts of cell death in the negative control despite many 
attempts at optimisation, making this option impractical to pursue. It is possible that 
the presence of RIP3 would allow for full membrane localisation of MLKL upon 
zVP24 expression. Increased levels of intracellular calcium  have been reported to 
occur during necroptotic death (Cai et al., 2014), however, given that we do not see 
increase in calcium levels in the cells [Figure 15], we believe that zVP24 may not be 
directly inducing necrotic cell death but could potentially sensitize the cells to this 
mode of death. This could happen if VP24 is either blocking apoptotic signalling 
pathways, eventually forcing the cell to enter necroptosis, or due to increase in 
reactive oxygen species (Christofferson and Yuan, 2010). However, we did not 




the project, though we did see caspase-8 activation, which is known to interact with 
RIP1 to mediate both apoptosis and necroptosis. Ultimately, it remains difficult to 
determine the intensity of VP24-induced MLKL phosphorylation without comparison 
to a known positive control necroptosis inducer. Therefore, we attempted to repeat 
the experiment with an extra sample of cells that have been treated with a cocktail 
of Z-VAD, an apoptosis inhibitor, SMAC mimetic BV6, an apoptosis inducer, and 
TNF-α, which together are known to activate the necroptosis pathway, however, we 
did not see MLKL phosphorylation and due to time constraints were unable to 
optimise the experiment. 
 
4.5 Conclusion 
Our observations from the previous chapter led us to hypothesise that cell death 
signalling pathways were being stimulated by expression of VP24. However, we can 
see with the current results that this hypothesis is not correct. Whilst zVP24 induces 
the activation of components of multiple cell death pathways (Caspase 8 cleavage, 
minor LC3 foci and MLKL phosphorylation), no cell death pathways were fully 
induced to the execution phase. There is the possibility VP24 may prime cells for 
cell death upon additional exposures or upon longer duration exposure to VP24. 
However, the initial live cell imaging results presented in Figure 11 highlight that the 
reduced cell densities may be either from increase cell death or decreased cell 
proliferation, which brings into question whether the cell cycle is being impaired by 
VP24 expression. Therefore, in order to reconcile the data found in chapter 3, our 
new hypothesis of VP24 cytotoxicity is that the protein negatively affects cell cycle. 
 
4.6 Future Work 
Despite not observing any activation of executioner caspases, it would be interesting 
to see if VP24 may have anti-apoptotic properties. Experiments whereby activation 
of the extrinsic apoptosis pathway by adding inducers into the cell culture medium 
such as Fas ligand or TNF-receptor apoptosis inducing ligand (TRAIL) in the 
presence of VP24 transfected cells, followed by western blotting the same 




informative since we observed activation of caspase 8 only. In addition, a follow up 
experiment regarding necroptosis would be warranted since we saw by western blot 
and increase in phospho-MLKL compared to rVP24. This would be repeated, 
possibly in a cell line that expresses endogenous RIP3 so that we could minimise 
the harshness of cell transfection, especially when restoring a cell death pathway. 
However, as the current data shows, we believe that its very unlikely VP24 induces 
cell death. As a result, moving onwards to cell cycle dysregulation would make more 






5 Cytotoxicity of VP24 – Cell Cycle 
5.1 Abstract 
 
Many viral proteins have been found to interfere with the cell cycle in order to 
dedicate host machinery towards viral replication, resulting in efficient generation of 
viral progeny. With regards to Ebola virus, nothing is known about whether there is 
a cell cycle arrest during infection. With the knowledge generated so far, we decided 
to assess for markers involved in cell cycle arrest in cells transfected with VP24 such 
as p21, a protein that is overexpressed to induce cell cycle arrest. We found that 
VP24 from both Zaire and Reston increases expression of p21 at 48 hours post 
transfection. This strongly suggests that a cell cycle arrest is taking place. We also 
detected an increase in γH2AX, a marker for DNA damage. This data suggests that 
the unreported cytotoxic effects of VP24 and the inability to generate a stable cell 
line is due to VP24 causing cell cycle arrest, which we consider to be a novel finding. 
We hope these observations would result in follow up research using live virus to 







In the first chapter of this investigation we had identified a decrease in metabolic 
activity by MTS assay and a decrease in cell density by live imaging. However, in 
the second chapter we did not observe activation of apoptosis, minimal activation of 
autophagy and inconclusive data regarding necroptosis activation. This leaves us to 
explore the last area we suspect that VP24 may be interfering with, the cell cycle. 
The cell cycle is split into four stages; G1 phase, S phase, G2 phase and M phase 
[Figure 22]. Within each of these phases, cyclins form complexes with cyclin-
dependant kinases (CDKs). The complexing of these proteins can be used to identify 
stages of cell cycle (Reddy, 2014). Many different proteins can promote or block cell 
cycle progression, depending on certain factors, such as DNA damage or pathogen-
host interactions. 
Many viruses have been known to modulate the cell cycle, such as HIV, which 
arrests cells in G2 phase, resulting in increased virus production (He et al., 1995). 
Thus, we decided to look for any evidence to suggest whether VP24 may affect cell 
cycle. Both mass spectrometry results from García-Dorival et al., 2014 and Batra et 
al., 2018 identified ANP32a as a binding partner of VP24. ANP32a protein has been 
shown to be involved in cell proliferation, through interactions with the retinoblastoma 
complex (Adegbola and Pasternack, 2005). Furthermore, we wondered whether the 
most well-known interactive partners of VP24; KPNA1 and KPNA5 were responsible 
for shuttling proteins into the nucleus that have important roles for cell cycle 
regulation. We then hypothesised that if VP24-KPNA1 or VP24-KPNA5 interactions 
prevents KPNA mediated nuclear import of STAT1, could there be another binding 





To verify changes in cell cycle we will use qPCR to check expression levels for 
cyclins. Cyclins are a family of proteins that have a regulatory role in cell cycle 
progression. Each cyclin is known to have distinct expression levels at various 
checkpoints of the cell cycle [Figure 22] as they form complexes with cyclin-
dependant kinases (CDK) to drive progression into the next stage. 
 
 
Cyclin Cell Cycle Stage 
Cyclin D1 G1 Phase 
Cyclin E Late G1/S phase transition 
Cyclin A S phase, G2/M phase transition 
Cyclin B Mitosis 
Figure 22 Cyclins during Cell cycle stages 
 
Expression levels of cyclins differ during the various stages of the cell cycle due 
to their regulatory role in progression from one stage to the next (A)(adapted 
from Vermeulen et al., 2003. Assaying expression levels of cyclins may offer 
insight as to what stage of the cell cycle the population is currently in. Our 







5.3.1 KPNA1 and KPNA5 Binding Partners using STRING database 
STRING is a database that shows reported protein-protein interactions based on the 
protein query that a user would be interested in. By using STRING database for 
interactive partners of KPNA1 and KPNA5, we screened for any protein that may 
have potential roles in cell cycle regulation [Figure 23]. We chose to use stringent 
filters for the listing of binding partners; so that we could collect datasets derived 
from experiments only, combined with high confidence threshold (≥0.700). The 
results identified ANP32B protein, from the same family as ANP32A, to interact with 
KPNA5. Current literature shows that ANP32A knockdown and ANP32B deficiency 






Figure 23. Binding Partners for KPNA1 and KPNA5 
By using STRING we screened for binding partners to KPNA1 (A) and KPNA5 (B) with 
the intention of identifying any protein by which impeding its nuclear import may result 
in adverse effects to the cells. By using datasets derived from experiments only, 
combined with high confidence threshold (≥0.700) we found the ANP32B protein that 







5.3.2 Analysis of cyclin mRNA expression levels 
To verify whether there is any change in cell cycle regulation, we opted to carry out 
a qPCR experiment to assess expression levels of cyclins using primers specific for 
Cyclins; A2, B1, D1, and E1. HeLa cells were transfected with either HA-tagged 
zVP24 or empty vector and incubated for 48 hours prior to lysis for RNA extraction. 
The CT values were analysed using excel and plotted on a graph to show fold 
changes against the mock samples that were transfected with empty vector plasmid. 
The results show that zVP24 expression causes an observable increased mRNA 
levels of Cyclin E1 comparable to the positive control generated by treating the cells 
with 500µM mimosine which arrests the cells at late G1 phase [Figure 25]. However 
statistical analysis did not reveal any significance as the p-value from an unpaired t-
test was 0.3346. As a result, it is suggestive but not conclusive that VP24 interferes 














Figure 24. Quantitative PCR analysis of Cyclin mRNA expression levels. 
Cells transfected with either HA-tagged zVP24, rVP24 or empty vector were lysed 
for RNA extraction at 48 hours post transfection. A positive control was generated 
by incubating mock transfected cells with 500µM mimosine for 24 hours to 
synchronise cells in G1 arrest. Melt curves for the water only samples tested 
negative for contamination during preparation for qPCR (A). Melt curves for primers 
specific to their target show similar Tm’s, which means they are amplifying one 
specific target (B). Fold changes of cyclin mRNA expression levels show increased 
Cyclin E1 in VP24 positive samples (C), suggesting that VP24 may be blocking 

























































5.3.3 VP24 expression leads to increase p21 expression 
As the qPCR experiments on cyclin mRNA levels were not able to conclusively prove 
VP24 alterations of cell cycle progression, we opted to carry out a western blot on 
p21, a cyclin-dependent kinase inhibitor that inhibits activity of cyclin-CDK 
complexes, resulting in cell cycle arrest. Our results show an increased expression 
level of p21 in both zVP24 and rVP24 samples compared to the mock, though zVP24 
appeared to induce p21 to slightly greater levels than rVP24 [Figure 25]. The strong 
induction of p21 also appears in the positive control where cells were arrested by 
500µM mimosine, a compound known to arrest cells in late G1 phase. Therefore, 
our results show that presence of VP24 increases intracellular levels of p21, likely 
leading to a cell cycle arrest at late G1. In addition, VP24 does not affect expression 
of cyclin E1 at the protein level, which was confirmed in figure 25.  
Figure 25. Western Blot for p21 expression levels 
To investigate dysregulation of cell cycle, Hela cells were transfected with either 
HA-tagged zVP24, rVP24 or empty pCAGGS vector for 48 hours prior to lysis. To 
block cells in G1 arrest 500μM mimosine was added to cells to generate a positive 
control sample. Cells transfected with zVP24 and rVP24 show increased 
expression of p21, suggesting that VP24 is blocking the cell cycle at G1 phase 





5.3.4 VP24 expression leads to DNA Damage 
In order to detect whether VP24 induces DNA damage that would then result in cell 
cycle arrest, we attempted to immunoblot against γH2AX, a biomarker for double-
strand DNA breaks. HeLa cells were transfected with either HA-tagged zVP24, 
rVP24 or empty vector and incubated for 48 hours prior to lysis for western blot. We 
detected increased signal intensity for γH2AX in both zVP24 and rVP24, whereas 
the negative control showed a weaker signal, therefore showing us that VP24 is 








Figure 26. Western Blot for DNA double strand breaks biomarker 
γH2AX. 
 
Double strand breaks of DNA damage lead to increased levels of γH2AX, a 
phosphorylated form of H2AX. To verify whether VP24 causes DNA 
damage, we transfected Hela cells for 48 hours prior to lysis with either 
zVP24, rVP24 and empty vector plasmid. Our immunoblot shows increased 
intensity of the γH2AX band compared to the mock control, suggesting that 








5.4.1 Cell Cycle Markers 
We had initially thought that by screening the mRNA levels of the different cyclins 
would give us insight into what stage of the cell cycle that cells would be in after 
transfection with VP24. However, literature has shown that in certain circumstances 
their expression levels are not directly correlated with cell cycle phase; for example, 
rapamycin induced G1 arrest in B-CLL cells was associated with decreased 
expression of cyclin E1, whereas histone deacetylase inhibitor FR901228 induced 
G1 arrest with increased expression of cyclin E1 (Sandor et al., 2000; Decker et al., 
2003). By taking this information into account, we still believe that qPCR of the 
different cyclins is important to examine in conjunction with Western blot analysis of 
protein expression [Figure 25]. In our experiments we can see that there is a non-
statistically significant increase in Cyclin E1 mRNA but not protein expression in the 
presence of VP24. Based on our initial screening of interacting partners presented 
in the introduction section of this chapter, we decided to probe for markers for G1 
arrest. p21, also known as WAF1/CIP1, is known to promote cell cycle arrest at G1 
and G2/M stage by inhibiting the cyclin-CDK complexes from forming (Karimian, 
Ahmadi and Yousefi, 2016). Multiple viruses have been reported to induce cell cycle 
arrest associated with p21 overexpression, such as HIV-1 Vpr protein, arresting cells 
at G2/M stag (Chowdhury et al., 2003). Furthermore, p21 has been shown to be 
overexpressed during activation of the DNA damage response, which then leads to 
cell cycle arrest (Karimian, Ahmadi and Yousefi, 2016). For these reasons we 
proceeded to blot for p21. The fact that p21 was overexpressed in both zVP24, 
rVP24 and the positive control suggests that VP24 may cause cell cycle arrest 
through modulation of p21 expression, further experiments need to be done to 
validate cell cycle arrest. The ideal experiment that should be carried out to ascertain 




during the time of this PhD project, we were unable to use the flow cytometer in the 
department. Whilst other chemicals and compounds can be used to induce G1 arrest 
such as thymidine by double blocking, we chose mimosine for its simplicity as it relies 
on a single treatment on cells and that it is G1 arrest specifically by p21 induction, 
which was detected by western blot in Figure 25.  
 
5.4.2 Detecting DNA Damage 
The overexpression of p21 had made us question the possibility of VP24 causing 
DNA damage in the cell. The localisation of VP24 in cells has predominantly been 
reported to be cytoplasmic, though a small minority of groups have reported nuclear 
localisation by immunofluorescence (F. He et al., 2017). In our experience, we do 
not detect any nuclear localisation of VP24, therefore we believe that the DNA 
damage caused by the protein is independent of its subcellular localisation. The 
biomarker for double strand breaks of DNA is phosphorylation of histone H2AX. Its 
phosphorylation by several kinases such as ataxia telangiesctasia mutated (ATM) 
and ATM-Rad3 related (ATR) result in recruiting DNA repair proteins into the nucleus 
(Kuo and Yang, 2008). Many viruses have been reported to interfere with the DNA 
damage response of the host cell, including negative sense single strand RNA 
viruses such as Influenza A virus, Rift Valley fever virus and La Crosse virus (Ryan 
et al., 2016). In the case of Rift Valley Fever virus, infection causes DNA damage 
via ATM kinase pathway. It was found that the subsequent cell cycle arrest stemming 
from the DNA damage was beneficial for viral replication (Baer et al., 2012). Whether 
VP24 is inducing DNA damage for the benefit of viral replication is yet to be 







The results presented in this chapter, in tandem with the live cell imaging and MTS 
in chapter 3, would suggest that VP24 is interfering with the cell cycle by causing 
DNA damage, leading to detection of γH2AX and overexpression p21. Whether the 
cell cycle is being blocked at a specific checkpoint is impossible to say at this stage 
and due to time constraints, we were not able to investigate further. Nonetheless, 
here we find the first pieces of evidence that VP24 is negatively affecting the cells, 
which is displayed via components of the DNA damage response pathway and likely 







5.6 Future Work 
 
The data gathered in the VP24 cytotoxicity chapter has given us a glimpse into how 
the protein is affecting the cell cycle and DNA damage response pathway. We find 
this very encouraging because to our knowledge, there is no literature focusing on 
Ebolaviruses and the DNA damage response pathway. Despite our data being 
preliminary with regards to the conclusion presented in Chapter 5, this thesis 
presents many experiments that returned negative results. We deem these results 
to be also of high value because it helps to remove possible biases and increase the 
validity of the positive results. For example, our MTS assay has shown a decrease 
in signal that was deemed to be statistically significant. Coupling the aforementioned 
results alongside the cell death pathways such as autophagic and apoptotic death 
which returned negative results gave us the impetus us to explore different avenues. 
This ultimately led us down the path of investigating cell cycle regulation and DNA 
damage, which we did not initially consider during this project. Ultimately, presenting 
scientific data that encompasses a mixture of negative and positive results helps to 
communicate a much broader overview of the project in question.  
 
In terms of future work, we would primarily centre the focus around p21, as its 
overexpression can indicate cell cycle arrest, DNA damage response and 
suppression of apoptosis. Therefore, the first experiment would be to carry out flow 
cytometry experiments with propidium iodide to ascertain if and where the cell cycle 
arrest occurs and in which stage. Following this, further data to support the evidence 
of the flow cytometry result, such as immunoprecipitating the CDK-cyclin complexes, 
as p21 can inhibit their formation. This would yield strong evidence with regards to 
cell cycle arrest. Subsequent experiments would include western blotting for 
expression levels of p53, as this would verify whether VP24 is overexpressing p21 
via p53 dependant or independent pathway, using suitable positive controls such as 
bleomycin, a drug that induces double strand breaks. We would also like to verify 
whether VP24 may localise in the nucleus to cause DNA damage, therefore carrying 
out a nuclear extraction treatment on VP24-transfected cells could give us more 




mutation in a particular residue or domain of the protein could be identified that would 
then abrogate the findings in this thesis. In this case we would attempt the same 
experiments using VP24 with mutations within the KPNA interacting domain, as this 
would tell us whether the phenotype we observed is dependent on these protein-
protein interactions. Lastly and most importantly, experiments using either the 
transcription and replication-competent viral-like-particle (trVLP) system or engaging 
with collaborators that have access to category 4 biocontainment labs for live virus 
experiments would have to be carried out in order to complete the full story because 
ultimately, why would the virus block the cell cycle or engage the DNA damage 
response pathways? Is it to modify the host cell for optimal viral replication or is it a 
self-defence mechanism of the infection by the host? These questions would help 
us understand pathogenic mechanisms during EBOV infection, and by comparing 
between non-human and human pathogenic strains we could hopefully understand 







6 Structure Function of the Ebola Virus Delta Peptide 
The Ebola virus delta-peptide is a viroporin, derived from proteolytic cleavage of 
sGP. Little is known about delta-peptide with regards to structure and function. Here, 
we decided to employ several different techniques to allow us to analyse the 
structure of delta peptide. We attempted to generate delta-peptide by recombinant 
methods using bacteria, which failed to generate the quantities required for suitable 
NMR methods. However, by purchasing synthetic delta-peptide in reduced form 
allowed us to attempt a unique type of crystallography called lipidic-cubic phase 
crystallography. This technique differs from traditional crystallography as it revolved 
around crystallisation in a lipid environment, a valuable technique for membrane 
bound proteins and peptides. We were successful in generating several crystals with 
different screening conditions, for both reduced and oxidised forms of the peptide. 
We hope to carry out X-ray scattering to derive a structure of the 23 amino acid c-
terminus Zaire delta-peptide and 25 amino acid c-terminus of Reston delta-peptide. 
This would allow us to investigate how their structures might result in pore formation 








The delta peptide of Ebolavirus is a small peptide produced during protein 
processing of sGP [Figure 28]. This occurs in the final stages of processing as the 
enzyme furin recognises a motif for cleavage on the C-terminus of sGP that results 
in mature sGP and delta peptide, both of which are secreted extracellularly 
(Volchkova, Klenk and Volchkov, 1999). The role of the delta-peptide is currently 
unknown, however bioinformatic analysis would suggest that it acts as a viroporin 
(J. He et al., 2017). Viroporins are peptides or proteins that are involved in 
pathogenesis and viral replication, of which their characteristic feature is forming 
pores in lipid bilayers. These pores can have ion-channel activity, as seen with 
Influenza Virus M2, forming a tetrameric channel that conducts protons, and 
rotavirus NSP4, which increases intracellular calcium (Nieva, Madan and Carrasco, 
2012). Viroporins are known to possess amphipathic helices, which are important 
for promoting insertion into membranes and forming pores when oligomerisation of 
multiple viroporins occurs.  In terms of viral replication, viroporins can alter 
membrane properties, allowing for morphogenesis and budding, as seen with 
Influenza Virus M2 (Rossman and Lamb, 2011). Current literature on the delta-
peptide is sparse. Since its discovery in 1999, only three studies have been 
completed. Whilst none have solved the structure of the delta-peptide, other 
properties have been investigated. Gallaher and Garry, 2015 conducted a 
bioinformatic analysis that modelled the structure of delta peptide from EBOV and 
RESTV. From their investigation, they identified a potential lytic activity of the 
peptide. He et al., 2017 used a synthetic peptide to determine its pore forming 
capability and lytic properties. They showed that the delta-peptide is active in an 
oxidised state, suggesting that formation of the disulphide bond between the 
cysteines is important for pore formation and insertion. Pokhrel et al., 2019 used 
molecular dynamics simulation to explore how oligomerisation states affect pore 
formation and activity. Their data suggests that hexameric pores can be formed that 




It is our intention to solve the structure of the 23-25 amino acid delta peptide fragment 
containing the suspected amphipathic structure of delta-peptide from both EBOV 
and RESTV, in oxidised and reduced states. We hope this structural determination 
would help shed more light on the function of the delta-peptide, its potential role in 
viral pathogenesis and show how the structure and function is affected by the 








Figure 27. Ebolavirus Delta-Peptide is a product of sGP processing. 
 
During expression of 7U GP gene, 80% of protein produced is sGP. This results in 
a furin-like cleavage site at position 324. Furin then cleaves the C-terminal end of 
sGP to yield a mature sGP protein and a ~40 amino acid Delta-Peptide (A). Delta-
peptide from both EBOV and RESTV contain a region in their C-termini believed 
to form an amphipathic structure (B). It is hypothesized that this structure could 
occur by the formation of a disulphide hairpin loop between the cysteines. (Panel 





6.2.1 TOCSY and NOESY NMR Imaging 
We first obtained chemically synthesised peptides corresponding to the last 23 C-
terminal amino acid residues for EBOV and last 25 C-terminal amino acid residues 
for RESTV in their reduced form. Then, before starting to collect spectrums on all of 
the delta-peptides from EBOV and RESTV in their reduced and oxidised states, we 
decided to carry out a total correlation spectroscopy (TOCSY) and nuclear 
overhauser effect spectroscopy (NOESY) experiment on the reduced EBOV delta 
peptide as a proof of concept. Therefore, we resuspended EBOV delta-peptide in 
ddH2O containing 20% acetic acid to a final concentration of 650μM and ran the 
experiments on the NMR machine. The spectra generated from the experiments 
show the peaks corresponding to the delta peptide, suggesting that this experiment 
is possible [Figure 28]. However, we would need to confirm whether the delta-
peptide interacts only superficially with the membrane, which would allow for non-
labelled NMR experiments, otherwise, in a situation whereby the peptide fully inserts 









Figure 28. TOCSY and NOESY NMR Spectra of reduced EBOV Delta-
Peptide 
To confirm whether in-solution NMR experiments could be carried out, we 
attempted to generate TOCSY (A) and NOESY (B) spectra of the EBOV delta-
peptide. Our spectra detected the delta-peptide, therefore these experiments 
can be carried out once we verify whether the peptide interacts superficially with 






6.2.2 Delta Peptide Membrane insertion 
To assess whether the structure of the delta peptide C-termini can be observed by 
NMR we first screened for membrane interactions using Nile Red stained giant 
unilamellar vesicles. The principle of unlabelled NMR based structure studies is that 
if the interactions remain superficial rather than full membrane insertion then it would 
be possible to generate the required spectra as the signal from the peptide would 
not be blocked by the lipid environment. However, full membrane insertion would not 
permit proton-proton experiments by NMR due to the signal generated by the lipids 
which would mask the signal generated from the peptide. Therefore, by using 
confocal microscopy we can understand the type of interaction with greater detail. 
Current research suggest full membrane insertion which would then require the 
generation of recombinant peptide with 13C and/or 15N labelling. We opted to 
generate GUVs using asolectin lipids as they contain a mixture of phospholipids. The 
results show insertion into the membrane as the FITC-delta peptide signal was 
present throughout the entire membrane, overlapping the red signal from the lipid 
bound dye [Figure 29]. This confirms previous results suggesting full membrane 
insertion and suggests why channel formation may be why the delta peptide has lytic 
properties (J. He et al., 2017). Due to this result, unlabelled NMR experiments would 
not be possible and so we endeavoured to generate recombinant labelled peptide 
for our NMR structural studies by using BL21 strain of Escherichia coli. For practical 
reasons, we opted to attempt this procedure using the EBOV delta peptide and, if 






















Nile Red FITC Merge 
Figure 29. Peptide Membrane interactions using Asolectin Lipid GUVs. 
20µM oxidised and reduced forms of FITC-labelled EBOV (E23) and RESTV (R25) 
delta peptides were incubated in the presence of Nile Red stained asolectin GUVs 
for 15 minutes prior to viewing on the confocal microscope. All forms of peptide 
colocalise with the GUV membranes which shows membrane insertion. This is 




6.3 Recombinant Production of 23 amino acid C-terminus Delta 
Peptide 
6.3.1 Gibson Assembly 
We opted to use a pCold bacterial expression vector from Ortega-Roldan research 
group for recombinant peptide production, due to the cold expression properties that 
reduces protease activity after induction to produce peptide in bacteria. To remove 
the delta-peptide gene insert from the pUC57 vector into a pCold vector expressing 
6x His tag, twin strep tag and GFP, Gibson assembly was carried out using the 
correct primers with overhangs. Two PCR reactions for amplifying our vector and 
construct were carried out, one for the pCold vector and one for the EBOV delta-
peptide. The thermocycler settings used are presented in Figure 31. We 
subsequently used a PCR cleanup kit to remove contaminants. However, we found 
that after PCR cleanup we did not see any of the 72bp fragment encoding the delta 
peptide. This is likely due to a minimum bp retention size of the membrane present 
in the PCR cleanup centrifugation tubes. Therefore, we attempted the experiment 
again, omitting the PCR clean up step and ran the product on a 3% TAE agarose 
gel treated with treated with SYBR Green to visualise DNA bands on the UV 
transilluminator [Figure 30].  
We detected a band around the 100bp marker for the sample that was not subjected 
to the PCR cleanup kit, therefore we decided to carry on the final steps of the Gibson 




This involved mixing our amplified products in a 1:4 ratio between amplified vector 
and amplified fragment, to a total 0.25pmols of DNA, followed by mixing with 2X 
Gibson Assembly Mastermix and volumes were raised to 20µL per PCR tube using 
ddH2O. The thermocycler settings were set to 50°C for 15 minutes as per 
manufacturer’s protocol. After the reaction, the resulting DNA solution in the tube 
was used to transform competent cells to generate plasmid DNA that was sent off 
for sequence to Eurofins to confirm successful generation of the plasmid to be used 








Figure 30. DNA Agarose Gel of delta-peptide PCR products 
Delta-peptide PCR products were mixed with 6X loading dye and 5µL were run 
on a 3% TAE Agarose gel stained with SYBR Safe Green DNA stain. *denotes no 
PCR cleanup sample. Control sample was water mixed with 6X loading dye. We 
detected a band around the 100bp marker for our construct that was not 




Figure 31. Thermocycler Settings for Gibson Assembly 
Construct Map of pCold vector expressing 6His-, twin-strep, GFP tagged EBOV Delta 
peptide (A).Conditions used to generate products for downstream Gibson assembly 
(B). The final product was sent for sequencing by Eurofins to verify successful 
assembly using custom primers from Jose Ortega-Roldan laboratory group (C). 
Sequences were aligned using SerialCloner software. Seq_1 denotes final product 








6.3.2 Purification by Nickel Column 
 
In order to produce pure GFP fused delta peptide, we first transformed BL21 
competent E. coli with pCold zDelta-peptide plasmid. Protein expression was 
induced with IPTG at 15°C overnight followed by lysis through sonication and debris 
removal by ultracentrifugation. In order to purify the GFP fused delta peptide, a 
series of column purification techniques were used; starting with a nickel column. 
The lysates were added to the column and all follow-throughs during purification 
were collected as the capture of the desired protein is never 100% efficient, and 
therefore allowing us to re-run any flowthroughs that were visibly green in order to 
maximise efficiency of peptide production, as the green colour indicated presence of 
GFP tagged delta peptide. After ultra-centrifugation was carried out to remove any 
cell debris, the lysate was initially purified through a nickel column due to the 
presence of a histidine tag. Two washes were carried out using wash buffer 
containing 5mM imidazole to remove any non-specific bound proteins. After the 2 
washes using 5 column volumes (CV) of wash buffer, the remaining bound proteins 
were eluted using 1CV of wash buffer containing 400mM imidazole, three times. 
Prior to starting the second step of purification by strep-tactin column to increase the 
purity of our sample for downstream application, we ran 10μL of lysates from each 
step on a tris-glycine gel and Coomassie stained to determine the purity of the 
samples [Figure 32]. We noticed that the elution portion of the purification still had 
many protein bands, suggesting that the purification has worked compared to the 
flowthrough sample, but not to optimum levels, as usually you would want to see a 
single band of your expressed protein. Following the result of the Coomassie stained 
gel, the elutions were subjected to a dialysis using a 7.5kD cutoff dialysis tubing. 
Dialysis was performed against 5 litres of lysis buffer overnight at 4°C using a 30kD 
cutoff dialysis tube in order to remove the imidazole present in the elution as this 







Figure 32. Nickel Column Purification of Delta Peptide 
BL21 cells were transformed with pCold GFP delta peptide and induced with IPTG 
overnight prior to lysis and purification by nickel column. 10µL of samples collected 
at each stage of the purification were subjected to gel electrophoresis using SDS-
PAGE Criterion™ TGX™ gels rated at AnyKD by the supplier (Biorad). Coomassie 
staining was carried out on the denaturing gel for four hours followed by overnight 
destaining at room temperature to assess purity. Most of the tagged peptide 
appeared in elution 2 and 3 but samples need further purification from background 
protein content due to the presence of multiple bands at different molecular 




6.3.3 Strep-Tactin purification  
To further purify the GFP-fused delta peptide we used a strep-tactin column as the 
construct expresses a twin strep tag. The column contained 5mL of packed beads, 
and was primed using the strep-tactin wash buffer prior to loading the lysate. 
Following the priming, the lysate eluted from the nickel column (elutions 2 and 3) 
was added to the column and washed using 10CV of wash buffer to remove any 
non-specific bound proteins. All flowthroughs were collected for analysis by 
Coomassie staining. To elute the bound GFP-fused peptide, 2.5mM of desthibiotin 
was added to the wash buffer and elution was carried out at 1CV in steps. Then, 
10μL of elutions were subjected to gel electrophoresis using a tris-glycine gel and 
~24 kD 
~31 kD 
Figure 33. Strep-Tactin Purification of Delta Peptide 
10µL samples were taken from each stage of strep-tactin purification and 
subjected to Coomassie staining on a denaturing gel to assess purity. Due 
to the purity of samples during elution 2 and 3 were used for TEV cleavage 
of peptide from the His-Strep-GFP tag. Red arrow points to the band 




Coomassie stained to determine the purity [Figure 33]. We saw two bands in the 
elutions. We suspect that the lower band is likely due to autocleavage of the TEV 
site, possibly due to presence of proteases still in the sample. 
 
6.3.4 TEV Cleavage 
 
 
In order to purify untagged delta peptide, the GFP tag needed to be removed, this 
could be performed though TEV cleavage at a site separating the GFP tag from the 
delta peptide. Therefore, we placed the elution in a 1kDa cutoff dialysis tubing 
containing lysis buffer containing 1mM EDTA, TEV enzyme and 1M DTT, at pH8. 
~24 kD 
~31 kD 
Figure 34. Confirming Cleavage from GFP tag using TEV enzyme 
Purified lysate containing the GFP-tagged delta peptide was subjected to TEV 
cleavage overnight at 4°C. After incubating the sample in the presence of TEV 
enzyme, aliquots were subjected to Coomassie staining on a denaturing gel to 
assess a difference in the height of the bands. We also attempted to detect the 




Dialysis was performed at 4°C overnight. The pH was chosen to be specifically high 
because when resuspending the synthetic delta-peptide we noticed that it was 
insoluble in water, and by adding 30% acetic acid, we successfully solubilised the 
peptide. We noticed that post dialysis there was a substantial amount of precipitate. 
We removed the green lysate solution, spun down the samples at 17,000G on a 
tabletop centrifuge for 15 minutes and resuspended the precipitate in 30% acetic 
acid at pH5 which caused the pellet to solubilise. In order to detected whether the 
delta-peptide was present at this point we subjected 0.5μL of resuspension to 
MALDI-TOF mass spectrometry analysis, against the solution remaining the dialysis 
tubing. We found that the peptide was indeed present in the solubilised pellet, and 
that none was present in the solution that was remaining in the dialysis tubing. As 
we have now confirmed the presence of the GFP cleaved delta peptide, the 
solubilised sample was run through a HPLC column.  
6.3.5 HPLC purification 
 
The last step to purify the peptide to a high purity, reverse phase HPLC using a was 
used whereby a gradient of solvent A (10% TFA in ddH2O) and B (1% TFA in 
acetonitrile) was subjected to the column containing the sample at a flow rate of 
4.5mL per second. Elutions were collected when the UV graph recorded a peak 
signal intensity, at 35 minutes. Elutions were also collected at minutes 36, 37 and 
38, as according to the elution profile, there was still presence of peptide [Figure 35]. 
Elutions were mixed into one tube and were lyophilised and resuspended in 30% 
acetic acid. The next step would be to verify that the fully cleaved 23aa peptide was 









After HPLC purification we verified that the peptide was present. The HPLC purified 
peptide sample was diluted 100x by using 1μL sample in 99μL TA solution, and 
0.5μL spotted onto the sample grid. Once the sample has dried on the anchorplate 
we added 0.5μL of matrix solution onto the dried spot containing the peptide. Then 
a calibration mix was added to an adjacent spot to calibrate the MALDI-TOF 
experiments for peptide detection around 300-3500MW. Using a 10% laser power, 
the MALDI-TOF was calibrated to detect peptides by firing the laser at the calibration 
spot, followed by firing the laser at our peptide samples that were eluted from the 
HPLC and in the supernatant after TEV cleavage [Figure 36]. The spectra obtained 
Figure 35. HPLC Elution graph of EBOV Delta Peptide 
Reverse phase HPLC was carried out to purify EBOV delta peptide. The elution 
profile taken at 280nm wavelength reveals peak elution of peptide at 35 minutes. 
The wavelength of 280nm detects aromatic compounds. The 23aa Zaire EBOV 
Peptide contains 3 amino acids with aromatic rings; 1 phenylalanine, 2 tryptophans 




from the supernatant after TEV cleavage showed no peptide was present, whereas 
the pellet from TEV cleavage that was resolubilised in 30% acetic acid and HPLC 
purified showed a small peak at molecular weight 3030.610, which corresponds to 
our peptide. The peptide peak was small, which could indicate that not much peptide 






Figure 36. MALDI-TOF analysis of peptide expression. 
The final step to verify production of the EBOV delta peptide was by using MALDI-TOF 
mass spectrometry. Post-TEV cleavage supernatant does not show the peak 
corresponding to the delta-peptide (A). However, the pellet that was resuspended in 
acetic acid and purified by HPLC showed a peak at molecular mass 3030.214 Daltons. 
This mass corresponds to the delta-peptide including 3 amino acids in the N-terminus 









We had initially planned to carry out in-solution NMR to determine the structure of 
the delta-peptide. The type of experiments for this would have been proton-proton 
experiments such as total correlation spectroscopy (TOCSY) and nuclear 
overhauser effect spectroscopy (NOESY). These experiments are based on the 
principle of determining signal from protons that are in close proximity to each other. 
However, proton signals stemming from the lipid membranes would mask signals 
generated from the protons in the synthetic peptide.  prior to NMR 
structural studies we deemed it was important to determine whether the peptide 
interacts with the surface or fully inserts into the lipid bilayer. It was for this reason 
that we initially screened for insertion using GUVs and FITC-tagged delta-peptide. 
Due to the results of the GUV peptide assay, it was clear that to be able to carry out 
structural studies of the delta peptide, it would have to be made recombinantly. We 
chose to use the pCold vector expressing a GFP fusion tag because having the 
peptide alone, which was proposed to be lytic, may become toxic to the BL21 cells 
when protein expression was induced, as this had been observed before with other 
lytic peptides during recombinant peptide production (Li, 2011). It is also of benefit 
to have used a GFP tag as during cell lysis by sonication, we could see a strong 
green coloured lysate, indicating successful protein expression. Furthermore, the 
pCold vector was chosen as induction of protein production occurs at low 
temperatures of 15°C, where host protease activity remains low, therefore greatly 
reducing the likelihood of proteolytic degradation. The version of the pCold vector 
obtained for these experiments also contained a x6 histidine tag and twin-strep tag. 
This allows for two rounds of different affinity chromatography techniques. Using a 
nickel bead purification column, we were able to greatly reduce the amount of 
background protein content in our lysates as nickel has affinity towards polyhistidine 
tags, reported to enrich samples up to100 fold in a single step (Bornhorst and Falke, 
2000). Subsequently, using a strep-tactin immobilisation column that binds with high 
affinity to strep tags, we were able to purify our sample to only contain our GFP fused 




the next step in peptide production which was using the TEV enzyme to cleave the 
GFP-fusion tag off the peptide. It was at this stage where we encountered difficulty. 
We had noticed that after cleavage, a substantial insoluble precipitate was present 
in the solution. We had originally thought this was due to trace impurities precipitating 
after cleavage. Our initial rounds of purification did not yield any peptide that was 
detectable by MALDI-TOF. However, after repeating the experiment, we subjected 
the TEV cleaved sample to centrifugation at >17,000 G to pellet all the precipitate, 
which was resolubilised by using 30% acetic acid at pH 5. It was this step that 
ultimately led to detectable levels of peptide by MALDI-TOF. We believe the 
precipitation occurred due to the basic pH of the buffer at which TEV cleavage was 
carried out, as we had noticed during resuspension of the synthetic peptide for our 
GUV experiments that without maintaining a pH lower that 6, the peptide would not 
dissolve in solution. This highlighted the importance of buffer composition for peptide 
production, as the conditions can greatly affect solubility. However, after we purified 
the resuspended pellet by HPLC, the samples were analysed by tris-glycine SDS-
PAGE to verify the presence of delta-peptide at roughly 3kD. Unfortunately we were 
not able to detect a band by Coomassie staining. Therefore, we quantified the 
concentration of peptide by spectophotometry, which was reported to be 65µM in a 
volume of 500µL. This meant that the production of this peptide requires large 
amounts of optimisation, such as pH ranges of buffers, different strains of bacterial 
cells, to produce 1mg/mL of peptide required for NMR studies, which was not 
possible due to time constraints of the PhD program. If there was more time to 
complete this project, we would start by optimising buffer pH’s, in particular during 
the TEV cleavage as the peptide crashed out when the pH was high. Otherwise, 
using a different expression vector containing fusion tags that enhance solubility 






6.5 Lipidic Cubic Phase Crystallography 
6.5.1 Introduction 
Lipidic cubic phase (LCP) crystallography is a technique that was developed to 
generate crystal structures of membrane proteins. Since membrane bound proteins 
possess both hydrophobic transmembrane domains and hydrophilic surfaces 
protruding from membranes, crystallisation in aqueous solutions has found to be 
very challenging since the hydrophobic domains rapidly aggregate to amorphous 
structures (Rummel et al., 1998). Whereas LCP provides a microenvironment that 
membrane bound proteins are more accustomed to, due to the presence of 
detergents, aqueous solutions and lipids. There are several lipid polymorphisms, as 
they may aggregate into membranes, liposomes, micelles for example (Luzzati and 
Tardieu, 1974). These different structures are referred to as phases, and the phase 
used for this particular type of crystallography is the cubic phase. This is because 
this phase possess properties that are favourable for protein crystallisation; they are 
macroscopically stable, solid and fully transparent materials (Landau et al., 1996). 
Owing to these properties, membrane proteins can be incorporated to these 
matrices. We decided that due to these properties, we could attempt to crystallise 
our delta-peptides using LCP crystallography. 
6.5.2  Results 
Due to reagent limitations, we decided to initially screen for the 25 amino acid 
RESTV delta-peptide in reduced form. Using commercially bought screens with 96 
different conditions, we screen two 96-well plates by mixing 30μL monoolein lipid 
with 10μL of peptide dissolved in 15% acetic acid to 20mg/ml. A Mosquito® Robot 
was used to pipette the lipid:peptide mixtures onto plates containing the 
commercially bought screens. After two weeks of incubation at 18°C, we detected 
four conditions that favoured crystal formation on one plate (MemGoldMeso™) 








0.2M Lithitum sulfate 
0.1M Phosphate/Citrate pH4.2 
10% w/v PEG 1000 
0.1M Sodium acetate Trihydrate 
0.1M Ammonium Fluoride 
0.1M MES Monohydrate pH 6 
30% v/v PEG 500 DME 







0.3M Lithium Sulfate 
0.1M HEPES pH 7 
35% v/v PEG 400 
0.35M Magnesium Chloride Hexahydrate 
0.15M Sodium Malonate Dibasic Monohydrate 
0.1M HEPES pH 7.5 
33% v/v PEG 400 
Figure 37. LCP crystallisation for R25red Delta Peptide with MemGoldMeso™ 
Screen 
30μl monoolein lipid was mixed with 10μL of peptide dissolved in 15% acetic acid and  
mixed with 96 different conditions from a MemGoldMeso™ screen plate for peptide 
crystallisation. Plates were monitored once a week for crystal formation under a light 
microscope. We found four conditions that favoured crystal formation from the 
MemGoldMeso™ screen. Crystals formed inside the bolus, increasing the likelihood that 







0.1M Sodium Chloride 
0.1M BICINE pH 9 
45% v/v PEG 500 MME  
0.4M Potassium Chloride 
0.05M HEPES pH 7.5 
12% v/v PEG 400  
0.1M BICINE pH 9 
30% v/v PEG 400  
Figure 38. LCP crystallisation for R25red Delta Peptide with MemGold2™ 
Screen 
30μL monoolein lipid was mixed with 10μL of peptide dissolved in 15% acetic acid 
and mixed with 96 different conditions from a MemGold2™ screen plate for peptide 
crystallisation. Plates were monitored once a week for crystal formation under a 
light microscope. We found four conditions that favoured crystal formation from the 
MemGoldMeso™ screen. Crystals formed inside the bolus, increasing the 









Due to success of crystal formation, the next stage would be to extract a structure of 
the peptide using X-ray diffraction. However, during crystallography, formation of salt 
crystals may occur. To differentiate the crystals between peptide or salts, we could 
employ several techniques. For example, polarisation lenses on microscopes can 
be used to check the birefringent properties of the crystals. Salts exhibit more 
birefringence than that of macromolecular crystals. However, our microscope does 
not possess a set of polarising planes. Therefore, our current plan would be to carry 
out X-ray diffraction on all of the crystals at Diamond Light Source, located at Harwell 
Science and Innovation Campus in Oxfordshire. Hopefully, these crystals will lead 
to the successful LCP crystallisation of the delta-peptide. 
 
6.6 Future Work 
Within the final 6 months of the project, our attempt to produce the 23aa C-terminal 
domain of the EBOV delta peptide was not completely successful. This is because 
recombinant peptide production has been reported to be fairly challenging. Despite 
this, we have attempted to crystallise our synthetic peptide using LCP 
crystallography. Due to detection of crystals, we hope to carry out x-ray diffraction 
experiments within a few months of submitting this thesis. If the crystals are indeed 
the delta-peptide, we will be able to generate a structure. Having the structure of the 
EBOV delta-peptide would allow us to understand how it inserts into membranes, 
which residues make contact to allow anchorage through the transmembrane, 
whether the shape of the peptide allows for ion channel activity. Furthermore, 
repeating the experiment with RESTV oxidised delta peptide as well as EBOV delta 
peptide, both in reduced and oxidised form, would allow us to compare between the 
non-human pathogenic species of Ebolavirus against the highly pathogenic Zaire 
Ebola virus species, which may give us insight towards the pathogenic determinants 





7 Concluding Remarks 
Ebolaviruses in Africa have repeatedly demonstrated their lethality through multiple 
recorded outbreaks, in contrast to the species found out of Africa which have never 
shown human pathogenicity. The race to understand the mechanisms behind 
infection, replication and pathogenicity has yielded a promising vaccine candidate. 
However, a vast expanse of knowledge is yet to be uncovered, as more filoviruses 
are being discovered around the world, ever increasing the members of the 
filoviridae, of which several members such as Reston virus and the newly discovered 
Bombali virus are non-pathogenic in humans. The thought that there are non-human 
pathogenic filoviruses, that often come into contact with humans due to the proximity 
of wildlife and local populations, is of increased interest. To date, nobody knows 
whether there is a simple mechanism that underpins the non-human pathogenic 
phenotype or whether it is due to a multitude of small differences between the strains 
that would make it so. Furthermore, the thought of non-pathogenic members of 
Ebolavirus genus becoming pathogenic due to mutations is terrifying, as the 
countries that they have been isolated in such as Philippines, has a very high density 
of human population. Throughout the course of this PhD we often compared and 
contrasted VP24 and delta-peptide between the human pathogenic Ebola virus and 
Reston virus, with the hopes to identify any difference within their interactions with 
the host cells or at a structural level. It would appear that for now, we can conclude 
that our experiments so far have not revealed any differences. To conclude, we are 
pleased to have revealed signs of a new mechanism of VP24 within host cells; 
modulation of cell cycle components. We also hope to solve the structures of all 
forms of the catalytically active C-termini of the delta-peptides, to shed light on 
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